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 ABSTRACT  
Increased activity of efflux transporters, e.g. P-glycoprotein (P-gp) and breast cancer resistance 
protein (BCRP), at the blood-brain barrier is a pathological hallmark of many neurological 
diseases, and the resulting multiple drug resistance represents a major clinical challenge. Non-
invasive imaging of transporter activity can help to clarify the underlying mechanisms of drug 
resistance, and facilitate diagnosis, patient stratification and treatment monitoring. We have 
developed a metabolically activated radiotracer for functional imaging of P-gp/BCRP activity 
with positron emission tomography (PET). In preclinical studies, the tracer showed excellent 
initial brain uptake and clean conversion to the desired metabolite, although at a sluggish rate. 
Blocking with P-gp/BCRP modulators led to increased levels of brain radioactivity; however, 
dynamic PET did not show differential clearance rates between treatment and control groups. 
Our results provide proof-of-concept for development of pro-drug tracers for imaging of P-
gp/BCRP function in vivo, but also highlight some challenges associated with this strategy. 
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 INTRODUCTION 
Membrane transporters at the blood-brain barrier (BBB) play an important role in maintaining 
this physiological barrier and hence, brain homeostasis: selective uptake transporters ensure the 
supply of essential nutrients like glucose, amino acids and nucleotides, whilst efflux transporters 
extrude toxic metabolites from the brain and prevent xenobiotics from reaching the central 
nervous system (CNS), thus providing a cellular detoxification system. The most prevalent efflux 
transporters at the BBB endothelium belong to the superfamily of adenosine triphosphate-
binding cassette (ABC) transporters, and include P-glycoprotein (P-gp; ABCB1) and breast 
cancer resistance protein (BCRP; ABCG2).1 P-gp and BCRP are located at the luminal 
membrane of the endothelial cells, where they extrude an array of structurally different 
compounds. Pharmacophore models developed for P-gp substrates suggest that compounds 
exhibiting two hydrogen bond acceptors, two aromatic rings and additional hydrophobic features 
are readily transported by the efflux pump.2 Recent research shows considerable overlap in 
substrate scope of P-gp and BCRP,3 and an increasing body of evidence suggests that they co-
localize and cooperate in transporting compounds at the BBB.4 Drug entry into the brain is 
therefore highly restricted, and is largely limited to compounds that are not recognized by efflux 
transporters and are able to cross the BBB by passive diffusion. In the course of many prevalent 
CNS disorders, especially refractory diseases like epilepsy, mood disorders and brain cancers, 
the delicate balance of transporter activity is distorted. The BBB becomes ‘leaky’, enabling toxic 
substances to temporarily reach the CNS, and, as a compensatory mechanism, activity and 
expression levels of efflux transporters increase.5 As a consequence of transporter upregulation 
at the BBB, CNS drug concentrations in the brain become too low to achieve a therapeutic effect. 
The resulting multiple drug resistance (MDR) affects 20–40% of all patients suffering from 
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 epilepsy, depression and schizophrenia, and is even more prevalent in drug refractory brain 
cancer and following human immunodeficiency virus infections.6  
Quantitative assessment of efflux pump function by positron emission tomography (PET) can 
help to clarify the underlying mechanisms of drug resistance in individual patients, and facilitate 
stratification of patients for specific treatment strategies. As P-gp/BCRP mediates extrusion of 
the most commonly prescribed CNS drugs,6c,7 a PET tracer that enables functional imaging of 
this transporter system can potentially be applicable to large patient cohorts spanning a range of 
diverse neurological diseases.  
In recent years, a number of strategies for imaging of drug efflux transporters have been 
evaluated. Tracers that have been designed as inhibitors, e.g. [11C]tariquidar and analogues, often 
act as substrates when administered in the low doses that are required for imaging with PET.8 
These P-gp/BCRP modulators, and P-gp substrates like [11C]verapamil all have significant 
limitations: poor metabolic stability, low brain uptake (substrates), low binding affinity 
(inhibitors), and insufficient selectivity make quantitative imaging of drug efflux pumps 
challenging.9 A more recent approach is the development of metabolically activated (pro-drug) 
tracers, as exemplified by carbon-11- and fluorine-18-labeled 6-halopurines for imaging of 
multidrug resistance protein 1.10 The so-called metabolite extrusion method (MEM) relies on 
passive diffusion of a pro-drug tracer into the organ of interest, e.g. the brain, its subsequent 
trapping by metabolic conversion into an efflux pump substrate (‘lock-in’ mechanism), and 
transporter-mediated extrusion of the metabolite.11 Provided that the physicochemical properties 
of the metabolite preclude passive diffusion across membranes, drug efflux transporter function 
can be directly correlated to the clearance rate of radioactivity from the target tissue, and hence 
readily be quantified by dynamic imaging. In order to allow MEM to be exploited for 
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 quantitative imaging of P-gp/BCRP function in vivo, a pro-drug tracer should have a high initial 
brain uptake and be rapidly transformed into a single radioactive metabolite that acts as a dual P-
gp/BCRP substrate, but does not interact with other transporters or targets in the brain. The 
radioactive metabolite should be unable to cross membranes by passive diffusion, so that in the 
absence of P-gp and BCRP, it is effectively trapped.9b  
Histamine H1 receptor (H1R) antagonists are widely used for the treatment of allergies, and are 
often characterized by their ability to cross the BBB: compounds of the first generation readily 
enter the brain causing H1R-mediated side effects, whereas substances of the second generation 
are avid P-gp substrates and hence give minimal exposure to the CNS.12 Interestingly, several 
H1R antagonists currently in clinical use are active metabolites of early generation drugs, e.g. 
cetirizine and fexofenadine are zwitterions formed by enzymatic oxidation of hydroxyzine and 
terfenadine, respectively.13 These well-characterized metabolic pairs of H1R antagonists were 
used as templates for the design of radiolabeled pro-drug tracers and metabolically activated dual 
P-gp/BCRP substrates (Figure 1).  
 
RESULTS & DISCUSSION 
Chemistry. Using the H1R antagonists fexofenadine and cetirizine as templates, a library of 
compounds was prepared (Scheme 1 and Scheme 2) in order to identify (i) structural motifs 
required for P-gp substrate activity, (ii) functionalities that could be exploited as pro-drug 
moieties for metabolic activation, and (iii) potential positions for labeling with fluorine-18 
(Figure 1). With the aim to circumvent the need for complex synthetic routes, 1-
benzhydrylpiperazine (scaffold A, derived from cetirizine) and diphenyl(piperidin-4-yl)methanol 
(scaffold B, derived from fexofenadine) derivatives decorated with benzylic and aliphatic side 
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 chains were initially evaluated. Scaffold B as well as its mono- and difluorinated analogues C 
and D, which were obtained by Grignard reactions with para-substituted piperidine derivatives 
(vide infra), were reacted with suitably functionalized benzylic halides by means of N-alkylation 
to give compounds 1, 3, 6, 9, 12, 14, and 16 (Scheme 1).14 The alkylating reagents were either 
commercially available, or prepared from the respective tolyl derivatives by radical bromination 
with N-bromosuccinimide. The alcohol 1 was further modified by Swern oxidation to obtain 
aldehyde 2,15 whereas hydrolysis of the esters 3, 6, 9, 12, 14, and 16 under basic conditions gave 
the corresponding carboxylic acids 4, 7, 10, 13, 15, and 17. 
A fluorinated aliphatic side chain was prepared as depicted in Scheme 2. Treatment of α-
hydroxy-γ-butyrolactone with DAST provided the fluorinated lactone 18,16 which after 
delactonization with methanol gave alcohol 19, albeit in moderate yield (20%).17 The alcohol 19 
was converted into the corresponding tosylate 20, which was used for subsequent N-alkylation of 
scaffolds A and B.18 The resulting esters 21 and 25 were either reduced to give alcohols 22 and 
26,
19 or hydrolysed to yield the acids 24 and 28.20 Finally, treatment of the alcohols 22 and 26 
with acetic anhydride provided the acyl esters 23 and 27. 
As biodistribution studies with [18F]23 and [18F]27 pointed to rapid defluorination of the 
aliphatic side chain in vivo (vide infra), a second set of compounds was designed consisting of 
fluorinated aromatic scaffolds and aliphatic side chains carrying pro-drug groups (alcohol, 
aldehyde and ester) as putative tracer candidates. To enable tuning of lipophilicity, additional 
scaffolds (C-F) were prepared (Scheme 3). Treatment of Boc-protected piperidine-4-carboxylic 
acid ethyl ester with 4-fluorophenylmagnesium bromide gave the difluorinated compound 33.21 
The corresponding mono-fluorinated analogue 32 was prepared from Boc-protected 4-
hydroxymethyl-piperidine using sequential oxidation and Grignard reactions.22 Deprotection of 
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 compounds 31-33 provided the mono- and difluorinated scaffolds 34, 35 and 37 (= scaffold C, D 
and F), whereas treatment of 32 with trifluoroacetic acid resulted in elimination of the tertiary 
alcohol to give compound 36 (= scaffold E). N-alkylation of scaffolds C, E and F with 
appropriately functionalized alkyl bromides provided the putative pro-drug tracers and non-
radioactive reference compounds 38–47 (Figure 2). 
In order to enable labeling of the putative tracers 23 and 27 with fluorine-18, the corresponding 
mesylate precursors 52 and 56 were prepared from a dioxolane building block (Scheme 4). The 
tosylate 48 was coupled to scaffolds A and B, and the resulting protected diols 49 and 53 were 
subsequently hydrolyzed under acidic conditions to give vicinal diols 50 and 54. Selective 
acetylation of the primary alcohol in compounds 50 and 54 was achieved with acetic anhydride 
to give the acetates 51 and 55, which upon mesylation gave the desired precursors 52 and 56, 
respectively. 
Whereas labeling of aliphatic groups with fluorine-18 is well established, aromatic 
[18F]fluorination of small molecules bearing complex functional groups remains a challenge.23 
Limitations of existing labeling methods prompted us to explore the use of sulfonium salts24 as 
leaving groups for aromatic [18F]fluorination of the scaffolds described above.25 For the 
synthesis of the sulfonium salts 62 and 64 bearing an electron deficient scaffold, the ketone 59 
was prepared by a lithium-mediated reaction of bromoarene 57 and Weinreb amide 58 (Scheme 
5). After Boc deprotection of 59, the desired side chains were introduced by N-alkylation, and 
the ammonium salts of the resulting diaryl thioethers 61 and 63 were treated with 
diphenyliodonium triflate in the presence of copper(II) benzoate to give the triarylsulfonium salts 
62 and 64, respectively. Labeling of compounds with the electron neutral scaffold E required 
decoration of the sulfonium salts with anisole moieties in order to achieve regioselective 
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 [18F]fluorination. The thioether 65 was converted into ketone 66 as described above. Addition of 
phenylmagnesium bromide to 66 provided alcohol 67, which upon treatment with trifluoroacetic 
acid yielded the deprotected 4-(methylene)piperidine 68. Following the route outlined above, N-
alkylation of 68 gave compounds 69, 71 and 73, which were converted into the corresponding 
triarylsulfonium salts 70, 72 and 74 using bis-(4-methoxyphenyl)iodonium triflate 75.26 
Radiochemistry. Radiolabeling of the mesylate precursors 52 and 56 (Scheme 6) with 
[18F]fluoride worked well in dimethyl sulfoxide under heating (20 min at 90 °C). Acetyl esters 
[18F]23 and [18F]27 were obtained in 40–50% analytical radiochemical yield (RCY) as 
determined by radio-HPLC. The isolated products were radiochemically pure but the specific 
activity was low (0.5 GBq/µmol) due to extensive decomposition of the respective precursors. 
As attempted hydrolysis of [18F]23 and [18F]27 to the corresponding alcohols [18F]22 and [18F]26 
further reduced the specific activity, the acetyl esters [18F]23 and [18F]27 were used for an initial 
biological evaluation of compounds [18F]22 and [18F]26 assuming that the esters would be 
rapidly cleaved by esterases in the blood after intravenous injection (Scheme 6). 
[18F]Fluorination of triarylsulfonium salts gave the highest radiochemical yields when using a 
combination of potassium bicarbonate, kryptofix and DMSO with heating to 110 °C for 15 
min.25 In the case of substrates containing electron withdrawing groups on the aromatic moiety, 
i.e. the ketones 62 and 64 (Scheme 7), the radiochemical reaction was exceptionally clean and 
yielded [18F]45 (36–40% decay-corrected isolated RCY, n = 3) and [18F]47 (22% decay-
corrected isolated RCY), respectively, without formation of any radioactive side products. 
Hydrolysis of [18F]45 afforded the alcohol [18F]46 (18% decay-corrected isolated RCY after two 
steps), whereas treatment of [18F]45 with phenylmagnesium bromide led to formation of the 
fexofenadine-like scaffold C with concurrent cleavage of the ester group to give the alcohol 
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 [18F]39 (16% decay-corrected isolated RCY after two steps). Subsequent reaction of [18F]39 with 
acetyl chloride provided the acyl ester [18F]38.  
Compounds containing the non-activated ritanserin-like scaffold E were prepared by direct 
labeling of the respective sulfonium salts 70, 72 and 74 with [18F]fluoride (Scheme 8). The 
resulting esters [18F]40a and [18F]43 as well as the acetal [18F]41 were hydrolyzed to give the 
alcohol [18F]40, the carboxylic acid [18F]44 and the aldehyde [18F]43, respectively. The 
radiochemical purity of the desired radiotracers ([18F]38-[18F]40, [18F]42-[18F]44, [18F]46 and 
[18F]47) was > 96%, however, the use of multi-step synthesis resulted in moderate overall yields 
(2–18% decay-corrected isolated RCY after formulation in saline). 
In our hands, preparation of sulfonium salts from the corresponding thioethers provided a 
practical and versatile synthetic method that gave rapid access to a number of structurally diverse 
precursors for labeling. Conveniently, triarylsulfonium salts are highly stable, easy to handle, and 
can readily be purified using conventional techniques including extractive aqueous workup and 
column chromatography on silica gel. In labeling studies, the precursors showed a remarkable 
reactivity with [18F]fluoride: activated substrates reacted at room temperature, and with heating 
the reaction proceeded in the presence of hydrogen bond donors. Furthermore, efficient and 
regioselective [18F]fluorination of non-activated aromatic moieties was achieved using sulfonium 
salts decorated with electron rich spectator ligands. The ability to label a spectrum of electron 
neutral to electron deficient aromatic groups with 18F in the presence of basic moieties, as well as 
hydrogen bond donors, makes the method broadly applicable to drug-like compounds, and hence 
opens up extensive pharmacological space for the design of small molecule PET tracers. 
In vitro compound screening. A luminescent P-gp ATPase assay was initially used to 
establish if the simplified fexofenadine derivatives retained the P-gp substrate activity of the 
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 parent compounds, and to identify putative metabolic pairs that could be exploited for the design 
of a pro-drug tracer. The assay allows rapid screening of P-gp substrate affinity, but the accuracy 
is insufficient to determine IC50 values.
27 In order to determine structural elements that are 
prerequisite to efflux pump substrate activity, ATP turnover triggered by the carboxylic acids 4, 
7 and 10 was compared to that of parent compound fexofenadine (Figure 3A). Of the test 
compounds, the benzoic acid 4 evoked the highest ATPase activity, which was similar to that of 
fexofenadine, whereas ketone 7 and isobutyric acid 10 appeared to be poor P-gp substrates. To 
evaluate functional groups for the design of pro-drug tracers, the benzylic alcohol 1, 
benzaldehyde 2, and benzoic ester 3 were tested (Figure 3B). The results pointed to a gradual 
increase in P-gp affinity with increasing oxidation state, with alcohol 1 resulting in modest ATP 
consumption, whereas the aldehyde 2 and ester 3 appeared to be more avid substrates. 
Remarkably, incorporation of fluorine into the benzoic moiety of 4 to give compound 13 
practically abolished the P-gp substrate affinity (Figure 3C). However, fluorine substituents on 
scaffold B were well tolerated, and the mono- and difluorinated derivatives 15 and 17 evoked 
ATP turnover comparable to that of compound 4. The use of a fluorinated aliphatic side chain, as 
for alcohol 22 and carboxylic acid 24, also appeared to be tolerated, and evoked ATP 
consumption to the same degree as their parent compounds hydroxyzine, and its metabolite 
cetirizine, respectively (Figure 3D). The results suggest that the zwitterions 4 and 24 are good P-
gp substrates, whereas the corresponding alcohols 1 and 22 are likely to evade active efflux, and 
hence are suitable leads for pro-drug tracer development. 
Tracer Evaluation in Vivo. The putative pro-drug tracers were evaluated using biodistribution 
studies in mice. The tissue distribution of radioactivity at 5 and 30 min post-injection (p.i.) was 
used to assess brain uptake, brain/blood ratios (Table 1), and the rate of clearance. Two 
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 derivatives labeled at the aliphatic side chain, namely [18F]23 (cetirizine-like scaffold A) and 
[18F]27 (fexofenadine-like scaffold B), were initially investigated to guide the choice of scaffold. 
As discussed above, we envisaged that ester hydrolysis would lead to rapid formation of the 
resulting alcohols [18F]22 and [18F]26 in vivo. Administration of [18F]23 and [18F]27 resulted in 
good initial uptake of radioactivity in the brain (5.8 and 7.2% injected dose per gram tissue 
(ID/g) at 5 min p.i., respectively), however, high uptake (3–6% ID/g at 30 min p.i.) was also 
observed in bone tissue (femur and skull) suggesting rapid enzymatic defluorination in vivo. 
Hence, we abandoned further evaluation of derivatives containing fluorinated aliphatic side 
chains, and instead evaluated pro-drug tracers bearing fluorine-18 at aromatic moieties. Indeed, 
administration of the acetate ester [18F]38, a structurally closely related analogue to [18F]27, 
exhibited far superior C-F bond stability as judged by the low level of radioactivity in bone tissue 
(< 2% ID/g at 30 min p.i.). However, the brain uptake and brain/blood ratio of alcohol [18F]39, as 
well as the corresponding acetyl ester [18F]38, were low. To improve the initial uptake of the pro-
drug tracer in the brain, we prepared an analogue of [18F]39 for which the hydroxyl group in 
scaffold B was replaced by an alkene to give scaffold E. The resulting pro-drug tracer [18F]40 
exhibited excellent initial brain uptake (9.4% ID/g at 5 min p.i.) with high brain/blood ratios 
(10.4 and 7.3 at 5 and 30 min p.i., respectively). In contrast, administration of the corresponding 
carboxylic acid [18F]44 resulted in an initial brain uptake of 1.3% ID/g at 5 min p.i. with a 
brain/blood ratio of 0.4. In accordance with the results from the in vitro assay, replacement of the 
alcohol with an aldehyde ([18F]42) or ester ([18F]43) as the pro-drug group proved futile, and 
resulted in moderate brain uptake (3.1 and 2.9 ID/g at 5 min p.i., respectively). Alcohol [18F]46, 
derived from scaffold F, showed good initial brain uptake (5.0% ID/g at 5 min p.i.), but brain 
clearance was rapid (1.8% ID/g at 30 min p.i.). The structurally related ester [18F]47 hardly 
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 penetrated the brain, most likely due to the rapid hydrolysis in vivo to give the corresponding 
carboxylic acid (70% conversion at 5 min p.i.).  
The 4-hydroxybutyl pro-drug tracer [18F]40 showed high initial brain uptake and a favorable 
clearance from the brain and was thus investigated further (Figure 4). The brain metabolism was 
exceptionally clean and gave the desired carboxylic acid [18F]44 as the only radioactive 
metabolite. The ratio of [18F]40 to [18F]44 in the brain decreased over time and was determined 
to be 6.1 at 30 min p.i., 1.5 at 60 min p.i., 0.6 at 90 min p.i. and 0.4 at 120 min p.i., respectively. 
However, as [18F]44 is extruded from the brain into the periphery, this ratio does not reflect the 
actual rate of metabolism. In the blood, oxidation of the alcohol was faster: whilst low amounts 
of [18F]40 were still detectable, [18F]44 constituted between 70 and 85% of total amount of 
radioactivity detected between 60 and 120 min p.i. (Figure 4C/D). Development of a MEM 
tracer requires that the radioactive metabolite does not cross the BBB to any significant extent by 
other mechanisms than extrusion by the targeted efflux pump. As the brain/blood ratios observed 
after administration of the carboxylic acid [18F]44 remained at or below 1.1 over the course of 
two hours after administration (Figure 4B), our results suggest that brain clearance from [18F]44 
is largely mediated by active efflux. However, a faster metabolism of the pro-drug tracer [18F]40 
would be desirable. The aldehyde [18F]42 and ester [18F]43 were designed as to accelerate 
formation of the carboxylic acid [18F]44 in vivo. Although metabolism to the zwitterions [18F]44 
was completed within five (ester) and 60 (aldehyde) minutes, respectively, their low brain/blood 
ratios rendered them unsuitable as pro-drug tracers (cf. Table 1). 
The pro-drug tracer [18F]40 was investigated further to determine if the corresponding 
metabolite [18F]44 acted as an efflux pump substrate in vivo. By injecting the dual P-gp/BCRP 
inhibitor tariquidar one to two hours prior to tracer administration at a dose of 15 mg/kg 
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 bodyweight it was ensured that P-gp was fully blocked over the course of the biodistribution 
studies (longest time point 120 min p.i.).28 The tariquidar dose is, however, not sufficiently high 
to fully inhibit BCRP. In a separate experiment, injection of elacridar (10 mg/kg bodyweight) 
was used to completely block both P-gp and BCRP.8c The comparison of the organ distribution 
without and with concomitant administration of tariquidar and elacridar, respectively (Figure 
5A), showed a similar brain uptake at 30 min p.i. (ca. 8% ID/g) in all animals, but revealed a 
significant effect on efflux pump inhibition at 60–120 min p.i.: when blocking with tariquidar, 
tracer brain uptake (in %ID/g) at 60 and 90 min p.i. was 30 and 50% higher than in untreated 
animals. Using elacridar, the amount of tracer in the brain was doubled between 60 and 120 min 
p.i. Tracer levels in the blood remained constant between 1 and 2% ID/g in all animals. The 
results provide evidence for active transport of the metabolically activated tracer [18F]44 across 
the BBB by P-gp as well as BCRP.  
Dynamic PET scans were performed in untreated mice, mice treated with either tariquidar or 
elacridar, and P-gp knockout mice (Figure 5B/C). Whole brain time-activity curves were fitted 
with the sum of a constant (irreversible compartment, representing the amount of tracer trapped 
in the brain) and a mono-exponential function (reversible compartment, representing the amount 
of tracer washed out from the brain and the efflux rate).29 For analysis and determination of 
efflux rates, data from 10 min p.i. onwards was used as this gave the best match between the 
fitted curves and the experimental results. Focusing on the time from 60 min p.i. onwards, i.e. 
when increasing formation of the metabolite [18F]44 was observed, did not change the 
quantitative outcome measure.  
In a first set of experiments (performed at AIT), untreated, tariquidar treated and P-gp 
knockout mice (Figure 5B) showed comparable initial brain uptake. The ratio of tracer that was 
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 washed out from the brain to tracer that was trapped (washout/trapped ratio) was similar in 
untreated and knockout mice (2.9 and 2.8, respectively), whereas in tariquidar treated mice, the 
washout/trapped ratio was lower (1.5). This suggests that more tracer was trapped in the brains 
of the treated mice. In a second set of experiments (performed at UCL), elacridar treated mice 
were compared to untreated animals and showed a lower washout/trapped ratio (2.3 versus 4.1). 
The marginally higher peak brain uptake in elacridar treated mice compared to the control group 
may have contributed to the increased amounts of radioactivity at later time points (Figure 5C). It 
should be noted that discrepancies between the two control groups (washout/trapped ratio of 1.5 
and 2.3, respectively) are most likely due to variations in the experimental setup. The difference 
in washout/trapped ratios provides evidence for [18F]44 acting as a dual P-gp/BCRP substrate, 
and the experiments in P-gp knockout mice suggest that BCRP can compensate for P-gp when 
extruding [18F]44. However, minor differences in efflux rates when comparing untreated and 
treated mice raise the possibility that not only tracer [18F]44 but also the pro-drug tracer [18F]40 
was washed out of the brain, either by passive diffusion or by active transport as an efflux pump 
substrate. 
Due to the complimentary and partially overlapping substrate scope of efflux pumps belonging 
to the large family of ABC transporters it is possible that transporters other than P-gp/BCRP 
contribute to the efflux of [18F]40/[18F]44.30 The tracer kinetics can also be affected by other 
factors such as off-target binding. Indeed, both the alcohol 40 and the carboxylic acid 44 showed 
high affinity to the human H1R (2.3 ± 0.4 and 18 ± 4 nM, respectively) as determined in an in 
vitro ligand displacement assay. The affinity to H1R may contribute to the retention of the pro-
drug tracer [18F]40 in the brain and may affect the rate of oxidative metabolism. Moreover, the 
metabolic activation, i.e. the conversion of [18F]40 to [18F]44, appeared to be slower than the 
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 extrusion of the metabolite [18F]44, and as a result there was no significant difference between 
the brain clearance rates of the control group and the two treatment groups. However, differences 
in the oxidizing rate of enzymes, as well as in efflux transporter distribution and function, may 
make [18F]40 more suitable as a pro-drug tracer in other species.31  
 
SUMMARY & CONCLUSIONS 
With the aim to develop a pro-drug tracer to enable dynamic imaging of P-gp/BCRP function 
in vivo, we used H1R antagonists as lead compounds to synthesize a library of putative pro-drug 
tracers and their corresponding metabolites. In biodistribution studies, derivatives containing a 
fluorinated aliphatic side chain were found to undergo rapid defluorination in vivo. The results 
prompted us to develop triarylsulfonium salts as novel precursors for aromatic labeling of drug-
like molecules with fluorine-18. This labeling strategy provided access to a range of putative 
pro-drug tracers and corresponding metabolites, and allowed identification of the alcohol [18F]40 
as a lead pro-drug tracer candidate. [18F]40 fulfills many of the requirements of MEM: it has 
excellent initial brain uptake (9.4% ID/g 5 min p.i.) and undergoes clean metabolic conversion to 
the desired carboxylate [18F]44 in the brain. Blocking experiments with the dual P-gp/BCRP 
inhibitors tariquidar and elacridar led to significantly increased levels of radioactivity in the brain 
in a period between 60 and 120 minutes after tracer injection, suggesting that the metabolite 
[18F]44 is a substrate for both P-gp and BCRP. However, there was no significant difference in 
the brain efflux rates between control animals and treatment groups as measured by dynamic 
PET. Because of the sluggish metabolic conversion and cross-reactivity with H1R we were not 
able to use [18F]40/[18F]44 for quantification of the efflux rate; however, the tracer is still likely 
to provide a qualitative depiction of regional brain efflux rates. 
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 Our results provide proof-of-concept for development of metabolically activated pro-drug 
tracers for imaging of P-gp/BCRP activity with PET. However, the results also highlight some of 
the challenges in achieving appropriate rates of enzymatic conversion and brain clearance. 
 
EXPERIMENTAL SECTION 
Chemistry. Reagents were purchased from Sigma-Aldrich, Acros Organics or Fluorochem and 
were used without further purification. Purification of non-labeled compounds by column 
chromatography was performed on silica unless otherwise specified. For characterization of non-
labeled compounds, 1H and 13C NMR spectra were recorded at room temperature unless 
otherwise specified. The respective instruments, Bruker Avance 400, 500 or 600 were operated 
at a frequency of 400, 500 or 600 MHz for 1H and 125 or 150 MHz for 13C, respectively. Proton 
decoupled 19F NMR spectra were recorded on a Bruker Avance 300 instrument at a frequency of 
282 MHz. All spectra were internally referenced to the respective deuterated solvents. Chemical 
shifts are reported in ppm and coupling constants (J) are given in Hertz (Hz). Full NMR 
assignment was performed with the aid of multidimensional and long range experiments. High 
resolution mass data were recorded on either a Thermo Finnigan MAT900xp (CI, EI) or a 
MALDI microMX (TOF) mass spectrometer. Melting points were taken on a Gallenkamp 
heating block and are uncorrected. Elemental analysis (C, H, N) was performed on a CE440 
analyser (Exeter Analytical). 
We have recently described the synthesis of compounds 29–32, 36, 37, 40, 43, 45, 46, 57–62, 
65–72 and 75.25 Compounds 18,16 34,32 3532 and 4833 have been described by others, and 
analytical data are in accordance with the published data. 
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 (1-(4-(Hydroxymethyl)benzyl)piperidin-4-yl)diphenylmethanol (1). Under inert 
atmosphere, diphenyl(piperidin-4-yl)methanol hydrochloride (2.1 g, 7.0 mmol), (4-
(chloromethyl)phenyl)methanol (1.0 g, 6.4 mmol), potassium carbonate (2.9 g, 21.0 mmol) and 
potassium iodide (0.1 g, 0.64 mmol) were heated in acetone (25 ml) for 6 h. After cooling the 
inorganic components were filtered off and the filtrate was purified by column chromatography 
(TEA 0.5%; DCM: methanol = 100: 0  98: 2). The resulting colorless oil was triturated with 
diethyl ether to give a white solid (0.3 g, 13%). Mp: 119 °C. 1H NMR (DMSO-d6, 500 MHz): δ 
7.48 (d, J = 7.4 Hz, 4H, ph’-2,6H), 7.29-7.22 (m, 8H, ph-2,3,5,6H, ph’-3,5H), 7.10 (t, J = 7.3 Hz, 
2H, ph’-4H), 5.24 (s, 1H, COH), 5.11 (t, J = 4.9 Hz, 1H, CH2OH), 4.46 (d, J = 5.5 Hz, 2H, 
CH2OH), 3.41 (br s, 2H, NCH2), 2.81 (br s, 2H, pip-2,6H
eq), 2.53-2.49 (m, 1H, pip-4H), 2.06 (br 
s, 2H, pip-2,6Hax), 1.49-1.47 (m, 2H, pip-3,5Hax), 1.24 (d, J = 11.1 Hz, 2H, pip-3,5Heq). 13C 
NMR (DMSO-d6, 125 MHz): δ 147.3 (ph’-1C), 128.7 (ph-1C), 127.8 (ph’-2,6C), 126.3 (ph’-4C), 
125.8 (ph-4C), 125.7 (ph’-3,5C, ph-2,3,5,6C), 78.5 (COH), 62.7 (CH2OH), 62.3 (NCH2), 53.3 
(pip-2,6C), 43.3 (pip-4C), 25.9 (pip-3,5C). HRMS (m/z): [M+H]+ calcd. for C26H29NO2, 
386.2120; found, 386.2129. Elemental analysis: calcd. for C26H29NO2 
. 0.75 H2O, C 77.87, H 
7.67, N 3.49; found, C 77.94, H 7.39, N 3.49. 
4-((4-(Hydroxydiphenylmethyl)piperidin-1-yl)methyl)benzaldehyde (2). Oxalyl chloride 
(0.22 ml, 2.6 mmol) was dissolved in DCM (5 ml) and the solution was cooled to < -50 °C. 
Under inert conditions, DMSO (0.22 ml, 3.1 mmol) dissolved in DCM (2 ml) was added 
dropwise and the solution was stirred for 15 min. Alcohol 1 (0.25 g, 0.65 mmol) dissolved in 
DCM (5 ml) was added and the solution was stirred for further 15 min. The reaction was 
quenched with TEA (0.8 ml, 5.7 mmol) and allowed to warm to room temperature. Water (30 
ml) was added and the solution extracted with DCM. The organic phase was dried (MgSO4), 
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 filtered, concentrated and crystallized using a mixture of petroleum ether: ethyl acetate = 3: 2 to 
give the product as a white solid (0.09 g, 34%). Mp: 149 °C. 1H NMR (DMSO-d6, 500 MHz): δ 
9.98 (s, 1H, CHO), 7.82 (d, J = 8.2 Hz, 4H, ph-2,6H), 7.53-7.48 (m, 6H, ph-3,5H, ph’-2,6H), 
7.23 (t, J = 7.8 Hz, 4H, ph’-3,5H), 7.10 (t, J = 7.3 Hz, 2H, ph’-4H), 5.23 (s, 1H, COH), 3.51 (s, 
2H, NCH2), 2.76 (d, J = 11.2 Hz, 2H, pip-2,6H
eq), 2.53-2.45 (m, 1H, pip-4H), 1.97 (t, J = 11.0 
Hz, 2H, pip-2,6Hax), 1.53-1.44 (m, 2H, pip-3,5Hax), 1.23 (d, J = 12.8 Hz, 2H, pip-3,5Heq). 13C 
NMR (DMSO-d6, 150 MHz): δ 192.8 (CHO), 147.3 (ph’-1C), 146.2 (ph-4C), 135.1 (ph-1C), 
129.5 (ph-2,6C), 129.2 (ph-3,5C), 127.8 (ph’-3,5C), 125.8 (ph’-4C), 125.8 (ph’-2,6C), 78.5 
(COH), 62.0 (NCH2), 53.6 (pip-2,6C), 43.3 (pip-4C), 26.0 (pip-3,5C). HRMS (m/z): [M+H]
+ 
calcd. for C26H27NO2, 386.2120; found, 386.2106. Elemental analysis: calcd. for C26H27NO2 
. 0.5 
H2O, C 79.16, H 7.15, N 3.55; found, C 78.95, H 6.90, N 3.48. 
Methyl 4-((4-(hydroxydiphenylmethyl)piperidin-1-yl)methyl)benzoate (3). Under inert 
atmosphere, diphenyl(piperidin-4-yl)methanol hydrochloride (2.0 g, 6.6 mmol), methyl 4-
(bromomethyl)benzoate (1.26 g, 5.5 mmol), potassium carbonate (2.73 g, 19.8 mmol) and 
potassium iodide were suspended in acetonitrile (50 ml) and refluxed overnight. After cooling to 
room temperature the inorganic components were filtered off and the filtrate was purified by 
column chromatography (TEA; DCM: methanol = 100: 0  98: 2). The product was obtained as 
a white solid (1.4 g, 61%). Mp: 116 °C. 1H NMR (DMSO-d6, 300 MHz): δ 7.87 (d, J = 8.2 Hz, 
2H, ph-2,6H), 7.48 (d, J = 7.6 Hz, 4H, ph’-2,6H), 7.41 (d, J = 8.2 Hz, 2H, ph-3,5H), 7.23 (t, J = 
7.7 Hz, 4H, ph’-3,5H), 7.09 (t, J = 7.3, 2H, ph’-4H), 5.25 (s, 1H, OH), 3.81 (s, 3H, OCH3), 3.47 
(s, 2H, NCH2), 2.74 (d, J = 10.8 Hz, 2H, pip-2,6H
eq), 2.50-2.43 (m, 1H, pip-4H), 1.94 (t, J = 11.0 
Hz, 2H, pip-2,6Hax), 1.54-1.43 (m, 2H, pip-3,5Hax), 1.23 (d, J = 12.1 Hz, 2H, pip-3,5Heq). 13C 
NMR (DMSO-d6, 75 MHz): δ 166.1 (C=O), 147.2 (ph’-1C), 144.6 (ph-4C), 129.0 (ph-2,6C), 
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 128.7 (ph-3,5C), 128.1 (ph-1C), 127.7 (ph’-3,5C), 125.7 (ph’-4C), 125.7 (ph’-2,6C), 78.4 
(COH), 61.8 (NCH2), 53.5 (pip-2,6C), 52.0 (OCH3), 43.3 (pip-4C), 25.8 (pip-3,5C). HRMS 
(m/z): [M+H]+ calcd. for C27H29NO3, 415.2142; found, 415.2131. Elemental analysis: calcd. for 
C27H29NO3, C 78.04, H 7.03, N 3.37; found, C 77.79, H 7.04, N 3.32. 
4-((4-(Hydroxydiphenylmethyl)piperidin-1-yl)methyl)benzoic acid (4). Compound 3 (1.0 g, 
2.4 mmol) was dissolved in methanol (2 ml) and THF (2 ml). Aqueous potassium hydroxide (2 
M, 4 ml) was added and the mixture was heated in the microwave oven for 15 min at 70 °C. 
After cooling the organic solvents were removed under reduced pressure and the aqueous 
solution neutralized with HCl. The product precipitated as white solid that was recrystallized 
from 2-propanol under addition of a drop of water (0.71 g, 74%). Mp: > 250 °C. 1H NMR 
(DMSO-d6, 500 MHz): δ 7.91 (d, J = 8.1 Hz, 2H, ph-2,6H), 7.53-7.48 (m, 6H, ph-3,5H, ph’-
2,6H), 7.24 (t, J = 7.7 Hz, 4H, ph’-3,5H), 7.11 (t, J = 7.3 Hz, 2H, ph’-4H), 5.54 (s, 1H, OH), 3.77 
(br s, 2H, NCH2), 2.95 (br s, 2H, pip-2,6H
eq), 2.58 (br s, 1H, pip-4H), 2.30 (br s, 2H, pip-2,6Hax), 
1.63-1.59 (m, 2H, pip-3,5Hax), 1.28 (d, J = 12.6 Hz, 2H, pip-3,5Hax). 13C NMR (DMSO-d6, 125 
MHz): δ 167.2 (C=O), 147.0 (ph’-1C), 139.8 (ph-4C), 130.3 (ph-1C), 129.8 (ph-3,5C), 129.3 
(ph-2,6C), 127.8 (ph’-3,5C), 125.9 (ph’-4C), 125.7 (ph’-2,6C), 78.4 (COH), 60.5 (NCH2), 52.7 
(pip-2,6C), 43.4 (pip-4C), 25.0 (pip-3,5C). HRMS (m/z): [M+H]+ calcd. for C26H27NO3, 
402.2069; found, 402.2085. Elemental analysis: calcd. for C26H27NO3 
. H2O, C 74.44, H 6.97, N 
3.34; found, C 74.28, H 6.64, N 3.34. 
Methyl 4-(2-bromoacetyl)benzoate (5). Methyl 4-acetylbenzoate (2 g, 0.011 mol) and p-
toluenesulfonic acid (0.2 g, 1.2 mmol) were suspended in anhydrous acetonitrile (10 ml). N-
Bromosuccinimide (2.2 g, 11.2 mmol) was added under inert conditions. The mixture was stirred 
for 15 min at room temperature and subsequently heated to 60 °C for 2 h. After cooling, the 
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 mixture was stirred in a mixture of water (50 ml) and toluene (50 ml) for 15 min. The organic 
layer was washed with brine, dried (MgSO4) and concentrated to dryness resulting in a light 
yellow solid, which was again washed with toluene to remove remaining bromine (67–85%). 
Mp: 78–80 °C. 1H NMR (DMSO-d6, 300 MHz): δ 8.02 (s, 4H, ph-2,3,5,6H), 3.82 (s, 3H, OCH3), 
2.60 (s, 2H, CH2). 
13C NMR (DMSO-d6, 75 MHz): δ 195.8 (C=O ketone), 165.6 (C=O ester), 
137.2 (ph-4C), 133.1 (ph-1C), 129.6 (ph-2,6C), 129.0 (ph-3,5C), 70.9 (ph-CH2), 57.7 (OCH3). 
HRMS (m/z): [M+H]+ calcd. for C10H9BrO3, 256.9813; found, 256.9818. 
Methyl 4-(2-(4-(hydroxydiphenylmethyl)piperidin-1-yl)acetyl)benzoate (6). Diphenyl-
piperidin-4-yl-methanol hydrochloride (1.3 g, 4.3 mmol), compound 5 (1.0 g, 3.9 mmol) and 
potassium carbonate (1.2 g, 8.7 mmol) were stirred in acetone (30 ml) at room temperature. After 
12 h the inorganic salts were filtered off and the filtrate concentrated under reduced pressure. 
The product was purified by column chromatography (TEA 0.5%; DCM: methanol = 100: 0  
98: 2). Re-crystallization from acetonitrile gave a yellow solid (0.5 g, 30%). Mp: 140 °C. 1H 
NMR (DMSO-d6, 500 MHz): δ 8.08-8.03 (m, 4H, ph-2,3,5,6H), 7.48 (d, J = 8.1 Hz, 4H, ph-
2,6H), 7.24 (t, J = 7.8 Hz, 4H, ph’-3,5H), 7.10 (t, J = 7.3 Hz, 2H, ph’-4H), 5.23 (s, 1H, OH), 3.87 
(s, 3H, OCH3), 3.77 (s, 2H, NCH2), 2.84 (d, J = 10.7 Hz, 2H, pip-2,6H
eq), 2.49 (overlay with 
DMSO peak, pip-4H), 2.10 (t, J = 11.1 Hz, 2H, pip-2,6Hax), 1.50-1.43 (m, 2H, pip-3,5Hax), 1.21 
(d, J = 12.3 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-d6, 125 MHz): δ 197.2 (C=O ketone), 165.6 
(C=O ester), 147.3 (ph’-1C), 139.4 (ph-4C), 133.1 (ph-1C), 129.3 (ph-2,6C), 128.5 (ph-3,5C), 
127.8 (ph’-3,5C), 125.7 (ph’-2,4,6C), 78.5 (COH), 64.6 (NCH2), 53.7 (pip-2,6C), 52.5 (OCH3), 
43.0 (pip-4C), 25.9 (pip-3,5C). HRMS (m/z): [M+H]+ calcd. for C28H29NO4, 444.2175; found, 
444.2172. 
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 4-(2-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)acetyl)benzoic acid (7). Compound 6 (0.3 
g, 0.7 mmol) was dissolved in methanol (1 ml) and THF (1 ml). Aqueous potassium hydroxide 
(2 M, 2 ml) was added and the mixture was heated in the microwave oven for 15 min at 70 °C. 
After cooling the organic solvents were removed under reduced pressure and the aqueous 
solution neutralized with HCl. The product precipitated as an off-white solid that was 
recrystallized from acetonitrile under addition of a drop of water (0.1 g, 35%). Mp: 187 °C. 1H 
NMR (DMSO-d6, 500 MHz): δ 8.04-8.00 (m, 4H, ph-2,3,5,6H), 7.48 (d, J = 8.0 Hz, 4H, ph’-
2,6H), 7.24 (t, J = 7.7 Hz, 4H, ph’-3,5H), 7.10 (t, J = 7.2 Hz, 2H, ph’-4H), 5.24 (s, 1H, OH), 3.80 
(s, 2H, NCH2), 2.86 (d, J = 9.2 Hz, 2H, pip-2,6H
eq), 2.49 (overlay with DMSO peak, pip-4H), 
2.14-2.10 (m, 2H, pip-2,6Hax), 1.52-1.47 (m, 2H, pip-3,5Hax), 1.22 (d, J = 11.6, 2H, pip-3,5Heq). 
13C NMR (DMSO-d6, 125 MHz): δ 197.0 (C=O ketone), 166.7 (C=O ester), 147.2 (ph’-1C), 
138.8 (ph-4C), 135.1 (ph-1C), 129.4 (ph-3,5C), 128.3 (ph-2,6C), 127.8 (ph’-3,5C), 125.8 (ph’-
4C), 125.7 (ph’-2,6C), 78.5 (COH), 64.4 (NCH2), 53.6 (pip-2,6C), 43.9 (pip-4C), 25.8 (pip-
3,5C). HRMS (m/z): [M-H]+ calcd. for C27H27NO4, 428.1862; found, 428.1843. Elemental 
analysis: calcd. for C27H27NO4 
. 0.5 H2O, C 73.95, H 6.44, N 3.19; found, C 74.10, H 6.23, N 
3.29. 
Methyl 2-(4-(bromomethyl)phenyl)-2-methylpropanoate (8). Under inert atmosphere, p-
tolylacetic acid (5 g, 0.033 mol) was dissolved in methanol (60 ml) and under cooling (ice bath) 
chlorotrimethyl silane (6.5 ml) was added dropwise. The solution was stirred overnight at room 
temperature and subsequently concentrated to dryness. The resulting colorless oil was dissolved 
in THF (25 ml) and added to a solution of sodium hydride (4 g, 60% dispersion in mineral oil, 
0.1 mol) in THF (100 ml). Methyl iodide (5 ml, 0.08 mol) was added dropwise and under 
cooling. The resulting suspension was stirred overnight at room temperature. After concentration 
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 to dryness the crude was taken up in water (50 ml) and extracted with ethyl acetate (3 x 50 ml). 
The organic layer was dried (MgSO4) and concentrated to give methyl 2-methyl-2-(p-
tolyl)propanoate (8a) as a yellow oil (4.6 g; 73%). 1H NMR (CDCl3, 300 MHz): δ 7.32 (d, J = 
8.3 Hz, 2H, ph-2,6H), 7.17 (d, J = 8.1 Hz, 2H, ph-3,5H), 3.66 (s, 3H, OCH3), 2.34 (s, 3H, ph-
CH3), 1.58 (s, 6H, C(CH3)2). 
13C NMR (CDCl3, 75 MHz): δ 177.4 (C=O), 141.8 (ph-4C), 136.3 
(ph-1C), 129.1 (ph-3,5C), 125.5 (ph-2,6C), 52.2 (OCH3), 46.2 (C(CH3)2), 26.6 (C(CH3)2), 21.0 
(ph-CH3). HRMS (m/z): [M+H]
+ calcd. for C12H16O2, 193.1229; found, 193.1236. A solution of 
2,2′-azobis(2-methylpropionitrile) in toluene (5 ml, 0.2 M) was concentrated to dryness without 
heating and under exclusion of light. 2,2′-Azobis(2-methylpropionitrile), N-bromosuccinimide 
(1.0 g, 5 mmol) and compound 8a (1.0 g, 5 mmol) were dissolved in bromobenzene or 
chlorobenzene (5 ml). The solution was heated in an oil bath kept at 110 °C. When the reaction 
mixture reached 80-90 °C, an exothermic reaction started with the development of bromine 
(orange color). Subsequently, the mixture turned dark brown and was quenched by cooling with 
an ice bath and adding ice water. The product was extracted with petrol. The organic layer was 
washed with brine, dried (MgSO4) and concentrated to dryness. The product was purified by 
column chromatography (petrol: ethyl acetate = 100: 0  98: 2) giving a yellow oil (50 – 61%). 
1H NMR (DMSO-d6, 300 MHz): δ 7.38 (d, J = 8.3 Hz, 2H, ph-2,6H), 7.29 (d, J = 8.4 Hz, 2H, 
ph-3,5H), 4.67 (s, 2H, CH2Br), 3.57 (s, 3H, OCH3), 1.48 (s, 6H, C(CH3)2). 
13C NMR (DMSO-d6, 
125 MHz): δ 176.4 (C=O), 142.9 (ph-4C), 140.9 (ph-1C), 126.6 (ph-2,6C), 125.1 (ph-3,5C), 62.5 
(CH2Br), 52.0 (OCH3), 46.0 (C(CH3)2), 26.4 (C(CH3)2). HRMS (m/z): [M-H]
+ calcd. for 
C12H15BrO2, 269.0172; found, 269.0163. 
Methyl 2-(4-((4-(hydroxydiphenylmethyl)piperidin-1-yl)methyl)phenyl)-2-methyl-
propanoate (9). Diphenyl(piperidin-4-yl)methanol hydrochloride (1.0 g, 3.3 mmol), compound 
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 8 (0.7 g, 2.6 mmol), potassium carbonate (1.46 g, 10.6 mmol) and potassium iodide (0.05 g, 0.33 
mmol) were suspended in acetonitrile (25 ml). Under inert atmosphere the mixture was refluxed 
overnight. After cooling the inorganic components were removed by filtration. The filtrate was 
concentrated to dryness and the crude purified by column chromatography (TEA 0.5%; DCM: 
methanol = 100: 0  98: 2). The product was isolated as colorless oil. 1H NMR (DMSO-d6, 500 
MHz): δ 7.48 (d, J = 7.6 Hz, 4H, ph’-2,6H), 7.29-7.18 (m, 8H, ph-2,3,5,6H, ph’-3,5H), 7.10 (t, J 
= 7.1 Hz, 2H, ph’-4H), 5.22 (s, 1H, OH), 3.56 (s, 3H, OCH3), 3.37 (s, 2H, NCH2), 2.75 (d, J = 
10.8 Hz, 2H, pip-2,6Heq), 2.49-2.44 (m, 1H, pip-4H), 1.91 (t, J = 11.3 Hz, 2H, pip-2,6Hax), 1.50-
1.43 (m, 8H, pip-3,5Hax, C(CH3)2), 1.23 (d, J = 12.2 Hz, 2H, pip-3,5H
eq). 13C NMR (DMSO-d6, 
125 MHz): δ 167.4 (C=O), 147.3 (ph’-1C), 143.0 (ph-1C), 137.0 (ph-4C), 128.7 (ph-3,5C), 
127.7 (ph’-3,5C), 125.8 (ph’-2,6C, ph-2,6C), 125.2 (ph’-4C), 78.5 (COH), 61.9 (NCH2), 53.5 
(pip-2,6C), 52.0 (C(CH3)2), 45.8 (OCH3), 43.4 (pip-4C), 26.4 (C(CH3)2), 25.5 (pip-3,5C). HRMS 
(m/z): [M+H]+ calcd. for C30H35NO3, 458.2695; found, 458.2696. 
2-(4-((4-(Hydroxydiphenylmethyl)piperidin-1-yl)methyl)phenyl)-2-methylpropanoic acid 
(10). Compound 9 (0.5 g, 1.0 mmol) was dissolved in methanol (1 ml) and THF (1 ml). Aqueous 
potassium hydroxide (2 M, 2 ml) was added and the mixture was heated in the microwave oven 
for 15 min at 70 °C. After cooling the organic solvents were evaporated and the aqueous solution 
neutralized with HCl. The product precipitated as white solid that was recrystallized from 
acetonitrile under addition of a drop of water (0.23 g, 48%). Mp: 246 °C. 1H NMR (DMSO-d6, 
500 MHz): δ 7.48 (d, J = 7.7 Hz, 4H, ph’-2,6H), 7.30-7.19 (m, 8H, ph-2,3,5,6H, ph’-3,5H), 7.09 
(t, J = 7.3 Hz, 2H, ph’-4H), 5.22 (s, 1H, OH), 3.39 (s, 2H, NCH2), 2.77 (d, J = 10.6 Hz, 2H, pip-
2,6Heq), 2.49-2.44 (m, 1H, pip-4H), 1.94 (t, J = 11.2 Hz, 2H, pip-2,6Hax), 1.50-1.43 (m, 8H, pip-
3,5Hax, C(CH3)2), 1.20 (d, J = 12.4 Hz, 2H, pip-3,5H
eq). 13C NMR (DMSO-d6, 125 MHz): δ 
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 177.6 (C=O), 147.3 (ph’-1C), 143.6 (ph-4C), 136.2 (ph-1C), 128.6 (ph-2,6C), 127.7 (ph’-3,5C), 
125.8 (ph’-2,6C, ph-3,5C), 125.3 (ph’-4C), 78.5 (COH), 61.9 (NCH2), 53.5 (pip-2,6C), 45.5 
(C(CH3)2), 43.3 (pip-4C), 26.4 (C(CH3)2), 25.9 (pip-3,5C). HRMS (m/z): [M+H]
+ calcd. for 
C29H33NO3, 444.2539; found, 444.2520. Elemental analysis: calcd. for C29H33NO3 
. 0.5 H2O, C 
76.96, H 7.57, N 3.09; found, C 77.19, H 7.38, N 3.09. 
Methyl 4-(bromomethyl)-3-fluorobenzoate (11). 3-Fluoro-4-methylbenzoic acid (2.0 g, 13.0 
mmol) was dissolved in methanol (20 ml). Chlorotrimethyl silane (2.6 ml) was added dropwise 
and under cooling and the mixture was stirred overnight at room temperature. The resulting 
crude was concentrated on silica and the product was purified by column chromatography 
(DCM). Methyl 3-fluoro-4-methylbenzoate (11a) was isolated as a colorless oil (1.4 g, 64%). 1H 
NMR (CDCl3, 500 MHz): δ 7.70 (d, J = 7.9 Hz, 1H, ph-6H), 7.64 (d, J = 10.2 Hz, 1H, ph-2H), 
7.23 (t, J = 7.7 Hz, 1H, ph-5H), 3.89 (s, 3H, OCH3), 2.29 (s, 3H, ph-CH3). 
13C NMR (CDCl3, 
125 MHz): δ 166.2 (C=O), 162.2 (d, 1JC,F = 118.8 Hz, ph-3C), 131.4 (d, 
3JC,F = 5.0, ph-5C), 
130.6 (d, 2JC,F = 17.3 Hz, ph-4C), 129.7 (d, 
3JC,F = 7.5 Hz, ph-1C), 125.1 (d, 
4JC,F = 3.6 Hz, ph-
6C), 116.1 (d, 2JC,F = 23.9 Hz, ph-2C), 52.2 (OCH3), 14.9 (d, 
3JC,F = 3.5 Hz, ph-CH3). 
19F NMR 
(CDCl3, 282 MHz): δ –117.16 (ph-F). HRMS (m/z): [M+H]
+ calcd. for C9H9FO2, 169.0665; 
found, 169.0662. A solution of 2,2’-azobis(2-methylpropionitrile) in toluene (10 ml, 0.2 M) was 
concentrated to dryness without heating and under exclusion of light. 2,2’-Azobis(2-
methylpropionitrile), N-bromosuccinimide (1.9 g, 10.0 mmol) and compound 11a (1.4 g, 8.3 
mmol) were dissolved in chlorobenzene and treated as described for compound 8, giving the 
desired product as yellow oil (1.5 g, quantitative conversion). 1H NMR (CDCl3, 500 MHz): δ 
7.80 (d, J = 8.0 Hz, 1H, ph-6H), 7.71 (d, J = 10.1 Hz, 1H, ph-2H), 7.46 (t, J = 7.7 Hz, 1H, ph-
5H), 4.51 (s, 2H, CH2Br), 3.92 (s, 3H, CH3). 
13C NMR (CDCl3, 125 MHz): δ 165.6 (C=O), 160.3 
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 (d, 1JC,F = 249.3, ph-3C), 132.5 (d, 
3JC,F = 7.9, ph-5C), 131.4 (d, 
2JC,F = 22.0, ph-4C), 130.1 (ph-
1C), 125.7 (ph-6C), 117.0 (d, 2JC,F = 23.1, ph-2C), 52.6 (OCH3), 24.6 (CH2Br).  
Methyl 3-fluoro-4-((4-(hydroxydiphenylmethyl)piperidin-1-yl)methyl)benzoate hydro-
chloride (12). Under inert atmosphere, diphenyl(piperidin-4-yl)methanol hydrochloride (2.0 g, 
6.6 mmol), compound 11 (1.5 g, 6.0 mmol) and potassium carbonate (2.7 g, 19.6 mmol) were 
suspended in acetonitrile (50 ml) and refluxed overnight. After cooling, the inorganic 
components were filtered off and the filtrate concentrated under reduced pressure. The product 
was purified by column chromatography (TEA 0.5%; DCM: methanol = 100: 0  98: 2). The 
oily product was crystallized with HCl in ethanol to give a white solid (1.7 g, 61%). Mp: 151–
154 °C. 1H NMR (DMSO-d6, 500 MHz): δ 10.72 (br s, 1H, NH
+), 7.91-7.84 (m, 2H, ph-5,6H), 
7.78 (d, J = 10.0, 1H, ph-2H), 7.45 (d, J = 7.5 Hz, 4H, ph’-2,6H), 7.26 (t, J = 7.7 Hz, 4H, ph’-
3,5H), 7.13 (t, J = 7.3 Hz, 2H, ph’-4H), 5.54 (s, 1H, OH), 4.32 (s, 2H, NCH2), 3.88 (s, 3H, 
OCH3), 3.36 (d, J = 11.1 Hz, 2H, pip-2,6H
eq), 3.02-2.95 (m, 2H, pip-2,6Hax), 2.81 (t, J = 11.7 
Hz, 1H, pip-4H), 1.83-1.76 (m, 2H, pip-3,5Hax), 1.42 (d, J = 13.7 Hz, 2H, pip-3,5Heq). 13C NMR 
(DMSO-d6, 125 MHz): δ 164.8 (C=O), 161.0 (d, 
1JC,F = 219.8 Hz, ph-3C), 164.5 (ph’-1C), 134.9 
(ph-5C), 133.1 (ph-4C), 127.9 (ph‘-3,5C), 126.1 (ph’-4C), 125.7 (ph’-2,6C), 125.2 (ph-6C), 
121.6 (ph-1C), 116.2 (d, 2JC,F = 23.8 Hz, ph-2C), 78.1 (COH), 56.0 (NCH2), 52.7 (OCH3), 51.4 
(pip-2,6C), 40.4 (pip-4C), 23.8 (pip-3,5C). 19F NMR (DMSO-d6, 282 MHz): δ –113.23 (ph-F). 
HRMS (m/z): [M+H]+ calcd. for C27H28FNO3, 434.2131; found, 434.2131. 
3-Fluoro-4-((4-(hydroxydiphenylmethyl)piperidin-1-yl)methyl)benzoic acid (13). 
Compound 12 (0.5 g, 1.0 mmol) was dissolved in methanol (1 ml) and THF (1 ml) and treated 
with aqueous potassium hydroxide (2 M, 2 ml). The mixture was heated in the microwave oven 
for 15 min at 70 °C. After cooling the organic solvents were removed under reduced pressure 
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 and the aqueous solution neutralized with HCl. The product precipitated as white solid that was 
recrystallized from acetonitrile under addition of a drop of water (0.15 g, 33%). Mp: 247 °C. 1H 
NMR (DMSO-d6, 500 MHz): δ 7.72 (d, J = 7.9 Hz, 1H, ph-6H), 7.58 (d, J = 10.4 Hz, 1H, ph-
2H), 7.50-7.48 (m, 5H, ph-5H, ph’-2,6H), 7.23 (t, J = 7.8 Hz, 4H, ph’-3,5H), 7.10 (t, J = 7.3 Hz, 
2H, ph’-4H), 5.24 (s, 1H, OH), 3.55 (s, 2H, NCH2), 2.79 (d, J = 11.0 Hz, 2H, pip-2,6H
eq), 2.50-
2.45 (m, 1H, pip-4H), 2.02 (t, J = 11.1 Hz, 2H, pip-2,6Hax), 1.52-1.44 (m, 2H, pip-3,5Hax), 1.23 
(d, J = 12.6 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-d6, 150 MHz): δ 166.3 (d, 
4JC,F = 2.3 Hz, 
C=O), 160.4 (d, 1JC,F = 243.9 Hz, ph-3C), 147.3 (ph’-1C), 132.2 (d, 
3JC,F = 7.2 Hz, ph-5C), 131.6 
(d, 3JC,F = 4.4 Hz, ph-1C), 129.8 (d, 
2JC,F = 13.1 Hz, ph-4C), 127.8 (ph‘-3,5C), 125.8 (ph’-4C), 
125.7 (ph’-2,6C), 125.1 (d, 4JC,F = 2.6 Hz, ph-6C), 115.7 (d, 
2JC,F = 23.6 Hz, ph-2C), 78.5 
(COH), 54.5 (NCH2), 53.3 (pip-2,6C), 43.1 (pip-4C), 25.9 (pip-3,5C). 
19F NMR (DMSO-d6, 282 
MHz): δ –117.833 (ph-F). HRMS (m/z): [M+H]+ calcd. for C26H26FNO3, 420.1975; found, 
420.1961. Elemental analysis: calcd. for C26H26FNO3 
. 0.5 H2O, C 79.16, H 7.15, N 3.55; found, 
C 78.95, H 6.90, N 3.48. 
Methyl 4-((4-((4-fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)methyl)benzoate 
(14). Under inert atmosphere, compound 34 (0.4 g, 1.24 mmol), methyl 4-
(bromomethyl)benzoate (0.43 g, 1.86 mmol) and potassium carbonate (0.43 g, 3.1 mmol) were 
suspended in acetone (15 ml) and stirred for 2 h at room temperature. The inorganic components 
were subsequently filtered off and the filtrate was concentrated under reduced pressure. 
Purification by column chromatography (TEA 0.5%; DCM: methanol = 100: 0  99: 1) gave the 
product as a colorless oil (0.19 g, 35%). 1H NMR (DMSO-d6, 600 MHz): δ 7.87 (d, J = 8.2 Hz, 
2H, ph-2,6H), 7.53-7.48 (m, 4H, ph’-2,6H, ph’’-2,6H), 7.42 (d, J = 8.2 Hz, 2H, ph-3,5H), 7.25 (t, 
J = 7.7 Hz, 2H, ph’-3,5H), 7.12 (t, J = 7.3 Hz, 1H, ph’-4H), 7.06 (t, J = 8.9 Hz, 2H, ph’’-3,5H), 
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 5.33 (s, 1H, COH), 3.83 (s, 3H, OCH3), 3.49 (s, 2H, NCH2), 2.77 (d, J = 8.1 Hz, 2H, pip-2,6H
eq), 
2.48 (t, J = 11.8 Hz, 1H, pip-4H), 1.95 (t, J = 11.8 Hz, 2H, pip-2,6Hax), 1.52-1.44 (m, 2H, pip-
3,5Hax), 1.21 (t, J = 11.5 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-d6, 150 MHz): δ 166.2 (C=O), 
160. 5 (d, 1JC,F = 240.6 Hz, ph’’-4C), 147.1 (ph’-1C), 144.7 (ph-4C), 143.5 (d, 
4JC,F = 2.7 Hz, 
ph’’-1C), 129.1 (ph-2,6C), 128.8 (ph’-3,5C), 128.2 (ph-1C), 127.9 (ph-3,5C), 127.7 (d, 3JC,F = 
7.7 Hz, ph’’-2,6C), 125.9 (ph’-4C), 125.7 (ph’-2,6C), 114.4 (d, 2JC,F = 20.7 Hz, ph’’-3,5C), 78.3 
(COH), 61.9 (NCH2), 53.5 (pip-2,6C), 52.1 (OCH3), 43.3 (pip-4C), 26.0 (pip-3,5C). 
19F NMR 
(DMSO-d6, 282 MHz): δ –118.08 (ph-F). HRMS (m/z): [M+H]
+ calcd. for C27H28FNO3, 
434.2131; found, 434.2122.  
4-((4-((4-Fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)methyl)benzoic acid (15). 
Compound 14 (0.18 g, 0.4 mmol) was dissolved in methanol (0.5 ml) and THF (0.5 ml). 
Aqueous potassium hydroxide (2 M, 1 ml) was added and the mixture was stirred overnight at 
room temperature. The organic solvents were evaporated and the aqueous solution neutralized 
with hydrogen chloride solution. The product precipitated as a white solid that was recrystallized 
from acetonitrile under addition of a drop of water (0.06 g, 35%). Mp: > 250 °C. 1H NMR 
(DMSO-d6, 600 MHz): δ 7.86 (d, J = 8.1 Hz, 2H, ph-2,6H), 7.53-7.48 (m, 4H, ph’-2,6H, ph’’-
2,6H), 7.39 (d, J = 8.1 Hz, 2H, ph-3,5H), 7.25 (t, J = 7.7 Hz, 2H, ph’-3,5H), 7.12 (t, J = 7.3 Hz, 
1H, ph’-4H), 7.06 (t, J = 8.9 Hz, 2H, ph’’-3,5H), 5.34 (s, 1H, OH), 3.49 (s, 2H, NCH2), 2.78 (d, J 
= 8.0 Hz, 2H, pip-2,6Heq), 2.48 (t, J = 11.9 Hz, 1H, pip-4H), 1.96 (t, J = 11.7 Hz, 2H, pip-
2,6Hax), 1.51-1.45 (m, 2H, pip-3,5Hax), 1.21 (d, J = 11.1 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-
d6, 150 MHz): δ 167.3 (C=O), 160.5 (d, 
1JC,F = 240.8 Hz, ph’’-4C), 143.9 (ph-4C), 143.5 (d, 
4JC,F 
= 2.6 Hz, ph’’-1C), 129.5 (ph-1C), 129.2 (ph-2,6C), 128.7 (ph’-3,5C), 127.9 (ph-3,5C), 127.7 (d, 
3JC,F = 7.8 Hz, ph’’-2,6C), 125.9 (ph’-4C), 125.7 (ph’-2,6C), 114.4 (d, 
2JC,F = 20.7 Hz, ph’’-
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 3,5C), 78.3 (COH), 61.9 (NCH2), 53.5 (pip-2,6C), 43.3 (pip-4C), 25.9 (pip-3,5C). 
19F NMR 
(DMSO-d6, 282 MHz): δ –118.09 (ph-F). HRMS (m/z): [M+H]
+ calcd. for C26H26FNO3, 
420.1975; found, 420.1964. Elemental analysis: calcd. for C26H26FNO3 
. 0.25 H2O, C 73.65, H 
6.30, N 3.30; found, C 73.39, H 6.13, N 3.27. 
Methyl 4-((4-(bis(4-fluorophenyl)(hydroxy)methyl)piperidin-1-yl)methyl)benzoate (16). 
Compound 35 (0.22 g, 0.65 mmol), methyl 4-(bromomethyl)benzoate (0.3 g, 1.3 mmol) and 
potassium carbonate (0.18 g, 1.3 mmol) were suspended in acetone (15 ml), refluxed overnight 
and stirred at room temperature for 24 h. The inorganic components were filtered off and the 
filtrate concentrated under reduced pressure. Purification by column chromatography (TEA 
0.5%; DCM: methanol = 98: 2) gave the product as a colorless oil (0.12 g, 41%). 1H NMR 
(DMSO-d6, 500 MHz): δ 7.87 (d, J = 8.3 Hz, 2H, ph-2,6H), 7.50-7.47 (m, 4H, ph’-2,6H), 7.40 
(d, J = 8.2 Hz, 2H, ph-3,5H), 7.10 (t, J = 8.9 Hz, 4H, ph’-3,5H), 5.38 (s, 1H, COH), 3.82 (s, 3H, 
OCH3), 3.47 (s, 2H, NCH2), 2.75 (d, J = 10.9 Hz, 2H, pip-2,6H
eq), 2.49-2.42 (m, 1H, pip-4H), 
1.94 (t, J = 11.2 Hz, 2H, pip-2,6Hax), 1.50-1.42 (m, 2H, pip-3,5Hax), 1.21 (d, J = 12.6 Hz, 2H, 
pip-3,5Heq). 13C NMR (DMSO-d6, 125 MHz): δ 166.2 (C=O), 160.5 (d, 
1JC,F = 241.3 Hz, ph’-
4C), 144.6 (ph-4C), 143.3 (ph’-1C), 129.1 (ph-2,6C), 128.8 (ph-3,5C), 127.7 (d, 3JC,F = 7.8 Hz, 
ph’-2,6C), 114.4 (d, 2JC,F = 20.9 Hz, ph’-3,5C), 78.1 (COH), 61.8 (NCH2), 53.4 (pip-2,6C), 52.0 
(OCH3), 43.3 (pip-4C), 25.9 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –117.89 (ph-F). 
HRMS (m/z): [M]+ calcd. for C27H27F2NO3, 452.2037; found, 452.2024. 
4-((4-(Bis(4-fluorophenyl)(hydroxy)methyl)piperidin-1-yl)methyl)benzoic acid (17). 
Compound 16 (0.5 g, 1.1 mmol) was dissolved in methanol (1 ml) and THF (1 ml). Aqueous 
potassium hydroxide (2 M, 2 ml) was added and the mixture was heated in the microwave oven 
for 15 min at 70 °C. After cooling the organic solvents were evaporated and the aqueous solution 
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 neutralized with HCl. The product precipitated as a white solid that was recrystallized from 
acetonitrile under addition of a drop of water (0.15 g, 31%). Mp: > 250 °C. 1H NMR (DMSO-d6, 
500 MHz): δ 7.85 (d, J = 8.2 Hz, 2H, ph-2,6H), 7.50-7.48 (m, 4H, ph’-2,6H), 7.38 (d, J = 8.2 Hz, 
2H, ph-3,5H), 7.09-7.04 (m, 4H, ph’-3,5H), 5.38 (s, 1H, OH), 3.48 (s, 2H, NCH2), 2.76 (d, J = 
11.1 Hz, 2H, pip-2,6Heq), 2.45 (t, J = 11.8 Hz, 1H, pip-4H), 1.96 (t, J = 11.0 Hz, 2H, pip-2,6Hax), 
1.50-1.42 (m, 2H, pip-3,5Hax), 1.21 (d, J = 12.5 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-d6, 125 
MHz): δ 167.3 (C=O), 160.5 (d, 1JC,F = 241.0 Hz, ph’-4C), 143.8 (ph-4C), 143.2 (ph’-1C), 129.5 
(ph-1C), 129.2 (ph-2,6C), 128.7 (ph-3,5C), 127.7 (d, 3JC,F = 7.9 Hz, ph’-2,6C), 114.4 (d, 
2JC,F = 
20.8 Hz, ph’-3,5C), 78.1 (COH), 61.8 (NCH2), 53.4 (pip-2,6C), 43.3 (pip-4C), 25.9 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –117.89 (ph-F). HRMS (m/z): [M+H]
+ calcd. for 
C26H25F2NO3, 438.1881; found, 438.1884. Elemental analysis: calcd. for C26H25F2NO3 
. 0.25 
H2O, C 70.65, H 5.82, N 3.17; found, C 70.67, H 5.67, N 3.25. 
3-Fluorodihydrofuran-2(3H)-one (18). Under inert atmosphere, 3-hydroxy-dihydro-furan-2-
one (2.0 g, 19.6 mmol) was dissolved in DCM (30 ml). DAST (3.9 ml, 29.4 mmol) was added 
dropwise at 0 °C. The solution was allowed to come to room temperature and stirred for 3 h at 
this temperature. The mixture was diluted with DCM and quenched with sodium bicarbonate 
solution at 0 °C. The separated organic layer was washed with brine and water, dried (MgSO4), 
filtered and concentrated to dryness. The product was purified by column chromatography 
(DCM) and was collected as colorless oil (1.15 g, 58%). 1H NMR (CDCl3, 500 MHz): δ 
5.23/5.13 (t/t, J = 7.7/7.7 Hz, 0.5H/0.5H, CHF), 4.50-4.46/4.32-4.27 (m/m, 1H/1H, CH2O), 2.72-
2.65/2.54-2.45 (m/m, 1H/1H, CHFCH2). 
13C NMR (CDCl3, 125 MHz): δ 171.8 (d, 
2JC,F = 20.9 
Hz, C=O), 85.3 (d, 1JC,F = 188.8 Hz, CHF), 64.9 (d, 
3JC,F = 5.9 Hz, CH2O), 29.5 (d, 
2JC,F = 20.0 
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 Hz, CHFCH2). 
19F NMR (CDCl3, 282 MHz): δ –196.16 (CHF). HRMS (m/z): [M+H]
+ calcd. for 
C4H5FO2, 105.0352; found, 105.0348.  
Methyl 2-fluoro-4-hydroxybutanoate (19). Compound 18 (1.73 g, 16.6 mmol) was dissolved 
in methanol (75 ml). Sodium methanolate (2.2 g, 41.5 mmol) was added in one portion. After 
stirring the solution for 1 h at room temperature it was quenched with HCl (2 N). Methanol was 
evaporated under reduced pressure and the product was subsequently extracted into ethyl acetate. 
Purification was performed by column chromatography (DCM: ethyl acetate = 10: 0  9: 1) 
giving the product as colorless oil (0.58 g, 26%). 1H NMR (CDCl3, 300 MHz): δ 5.20/5.04 
(dd/dd, J = 7.3/7.0 Hz, 0.5H/0.5H, CHF), 3.90-3.70 (m, 2H, CH2OH), 3.80 (s, 3H, OCH3), 2.26-
2.08 (m, 2H, CHFCH2). 
13C NMR (CDCl3, 150 MHz): δ 170.8 (d, 
2JC,F = 23.4 Hz, C=O), 86.5 
(d, 1JC,F = 168.5 Hz, CHF), 57.8 (d, 
3JC,F = 4.1 Hz, CH2OH), 52.8 (OCH3), 35.1 (d, 
2JC,F = 20.6 
Hz, CHFCH2). 
19F NMR (CDCl3, 282 MHz): δ –195.16 (CHF). HRMS (m/z): [M+H]
+ calcd. for 
C5H9FO3, 137.0614; found, 137.0610. 
Methyl 2-fluoro-4-(tosyloxy)butanoate (20). Compound 19 (0.78 g, 5.9 mmol) was dissolved 
in DCM (30 ml) and the solution was cooled to 0 °C. Pyridine (0.51 ml, 6.2 mmol) and tosyl 
chloride (1.2 g, 6.2 mmol) were subsequently added. The mixture was stirred overnight at room 
temperature. It was diluted with DCM and the reaction was quenched with water. The separated 
organic layer was washed with brine, dried (MgSO4) and concentrated under reduced pressure. 
The product was purified by column chromatography (DCM) giving a colorless oil (0.43 g, 
25%). 1H NMR (CDCl3, 600 MHz): δ 7.78 (d, J = 8.3 Hz, 2H, ph-3,5H), 7.37 (d, J = 8.0 Hz, 2H, 
ph-2,6H), 5.03/4.95 (dd/dd, J = 8.4/8.5 Hz, 0.5H/0.5H, CHF), 4.19-4.15 (m, 2H, CH2O), 3.78 (s, 
3H, OCH3), 2.45 (s, 3H, ph-CH3), 2.36-2.15 (m, 2H, CHFCH2). 
13C NMR (CDCl3, 150 MHz): δ 
169.5 (d, 2JC,F = 23.3 Hz, C=O), 145.3 (ph-4C), 132.6 (ph-1C), 130.1 (ph-2,6C), 128.1 (ph-
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 3,5C), 85.0 (d, 1JC,F = 184.4 Hz, CHF), 64.9 (d, 
3JC,F = 3.6 Hz, CH2O), 52.8 (OCH3), 32.1 (d, 
2JC,F = 20.9 Hz, CHFCH2), 21.8 (ph-CH3). 
19F NMR (CDCl3, 282 MHz): δ –195.79 (CHF). 
HRMS (m/z): [M+H]+ calcd. for C12H15FO5S, 291.0703; found, 291.0692.  
Methyl 4-(4-benzhydrylpiperazin-1-yl)-2-fluorobutanoate (21). TEA (0.2 ml, 0.5 mmol) 
was dissolved in dry acetonitrile. Under inert atmosphere, 1-benzhydryl-piperazine (0.37 g, 1.49 
mmol) and compound 20 (0.43 g, 1.49 mmol) were subsequently added. The solution was stirred 
for 6 h at 70 °C. After cooling it was concentrated to dryness and the product was purified by 
column chromatography (TEA; DCM: methanol = 99: 1) giving a light yellow oil (0.22 g, 40%). 
1H NMR (DMSO-d6, 600 MHz): δ 7.40 (d, J = 7.4 Hz, 4H, ph-2,6H), 7.28 (t, J = 7.6 Hz, 4H, ph-
3,5H), 7.17 (t, J = 7.4 Hz, 2H, ph-4H), 5.17/5.09 (t/t, J = 5.4/5.4 Hz, 0.5H/0.5H, CHF), 4.25 (s, 
1H, benzh.-CH), 3.67 (s, 3H, OCH3), 2.50-2.15 (m, 10H, prz-2,3,5,6H2, NCH2), 1.98-1.93 (m, 
2H, CHFCH2). 
13C NMR (DMSO-d6, 150 MHz): δ 169.9 (d, 
2JC,F = 23.7 Hz, C=O), 142.9 (ph-
1C), 128.5 (ph-3,5C), 127.6 (ph-2,6C), 126.9 (ph-4C), 87.0 (d, 1JC,F = 179.7 Hz, CHF), 75.1 
(benzh.-CH), 55.0 (NCH2), 52.8 (prz-2,6C), 52.0 (OCH3), 51.5 (prz-3,5C), 29.1 (d, 
2JC,F = 20.6 
Hz, CHFCH2). 
19F NMR (DMSO-d6, 282 MHz): δ –193.32 (CHF). HRMS (m/z): [M+H]
+ calcd. 
for C22H27FN2O2, 371.2135; found, 371.2140.  
4-(4-Benzhydrylpiperazin-1-yl)-2-fluorobutan-1-ol dihydrochloride (22). Lithium 
aluminium hydride (0.031 g, 0.81 mmol) was dissolved in THF (5 ml). Compound 21 (0.1 g, 
0.27 mmol), dissolved in THF (5 ml), was added dropwise under inert atmosphere. The mixture 
was stirred 1 h at room temperature and subsequently quenched with brine. THF was evaporated 
and the aqueous solution was adjusted to pH = 10 using aqueous NaOH (2 N). The product was 
extracted into DCM. Drying (MgSO4) and concentration afforded a colorless oil (0.08 g, 87%). 
The product was crystallised with HCl in ethanol and precipitated as white solid (0.046 g, 42%). 
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 Mp: 209 °C. 1H NMR (DMSO-d6, 400 MHz, 80 °C): δ 7.68 (d, J = 7.2 Hz, 4H, ph-2,6H), 7.38 (t, 
J = 7.5 Hz, 4H, ph-3,5H), 7.29 (t, J = 7.3 Hz, 2H, ph-4H), 5.09 (br s, 1H, benzh.-CH), 4.71-
4.66/4.59-4.54 (m/m, 0.5H/0.5H, CHF), 3.64-3.53 (m, 2H, CH2OH), 3.48 (s, 4H, prz-2,6H2), 
3.23 (t, J = 8.0 Hz, 2H, NCH2), 3.05 (s, 4H, prz-3,5H2), 2.18-2.07 (m, 2H, CHFCH2). 
13C NMR 
(DMSO-d6, 150 MHz): δ 135.3 (ph-1C), 129.3 (ph-3-5C), 128.2 (ph-2,6C), 92.1 (d, 
1JC,F = 169.1 
Hz, CHF), 74.1 (benzh.-CH), 62.5 (d, 2JC,F = 19.7 Hz, CH2OH), 52.1 (NCH2), 48.5 (prz-2,6C), 
44.2 (prz-3,5C), 25.2 (CHFCH2). 
19F NMR (CDCl3, 282 MHz): δ –188.20 (CHF). HRMS (m/z): 
[M+H]+ calcd. for C21H27FN2O, 343.2186; found, 343.2184. Elemental analysis: calcd. for 
C21H27FN2O 
. 2 HCl . 0.25 H2O, C 60.07, H 7.08, N 6.69; found, C 60.72, H 7.04, N 6.74. 
4-(4-Benzhydrylpiperazin-1-yl)-2-fluorobutyl acetate (23). Compound 22 (liberated base; 
0.1 g, 0.29 mmol) was dissolved in DCM (5 ml). TEA (43 μl, 0.3 mmol) and acetic anhydride 
(35 μl, 0.3 mmol) were added under cooling (ice bath). The mixture was stirred 3 h at room 
temperature and subsequently quenched with aqueous NaOH (2 M). The organic layer was dried 
(MgSO4), filtered and purified by column chromatography (TEA; DCM: methanol = 99.5: 0.5). 
The product was isolated as colorless oil (0.09 g, 80%). 1H NMR (DMSO-d6, 300 MHz): δ 7.41 
(d, J = 7.3 Hz, 4H, ph-2,6H), 7.27 (t, J = 7.5 Hz, 4H, ph-3,5H), 7.16 (t, J = 7.2 Hz, 2H, ph-4H), 
4.83-4.63 (m, 1H, CHF), 4.23 (s, 1H, benzh.-CH), 4.17-4.03 (m, 2H, CH2OCOCH3), 2.52-2.26 
(m, 10H, prz-2,3,5,6H2, NCH2), 2.02 (s, 3H, COCH3), 1.81-1.65 (m, 2H, CH2CH). 
13C NMR 
(DMSO-d6, 150 MHz): δ 170.2 (C=O), 143.0 (ph-1C), 128.6 (ph-3,5C), 127.6 (ph-2,6C), 126.9 
(ph-4C), 90.1 (d, 1JC,F = 170.0 Hz, but-2C), 75. 2 (benzh.-CH), 65.4 (d, 
2JC,F = 20.4 Hz, but-1C), 
53.0 (d, 3JC,F = 5.2 Hz, but-4C), 52.8/52.7 (prz-2,6C), 51.6 (prz-3,5C), 28.0 (d, 
2JC,F = 20.4 Hz, 
but-3C), 20.6 (COCH3). 
19F NMR (DMSO-d6, 282 MHz): δ –186.59 (CHF). HRMS (m/z): 
[M+H]+ calcd. for C23H29FN2O2, 384.2213; found, 384.2210.  
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 4-(4-Benzhydrylpiperazin-1-yl)-2-fluorobutanoic acid (24). Compound 21 (0.1 g, 0.27 
mmol) was dissolved in methanol (0.5 ml) and THF (0.5 ml). Aqueous potassium hydroxide (2 
M, 1 ml) was added and the mixture was stirred overnight at room temperature. The organic 
solvents were evaporated and the aqueous solution neutralized with hydrogen chloride solution. 
The product precipitated as a white solid that was recrystallized from acetonitrile under addition 
of a drop of water (0.05 g, 49%). Mp: 227–230 °C (carbonization). 1H NMR (DMSO-d6, 600 
MHz): δ 7.38 (d, J = 7.6 Hz, 4H, ph-2,6H), 7.25 (t, J = 7.5 Hz, 4H, ph-3,5H), 7.15 (t, J = 7.2 Hz, 
2H, ph-4H), 4.95/4.87 (t/t, J = 5.8/5.8 Hz, 0.5H/0.5H, CHF), 4.39 (s, 1H, benzh.-CH), 3.50 (br s, 
4H, prz-2,6H2), 3.36-3.31/3.23-3.17 (m/m, 1H/1H, NCH2), 2.99 (br s, 4H, prz-3,5H2), 2.39-2.22 
(m, 2H, CHFCH2). 
13C NMR (DMSO-d6, 150 MHz): δ 171.0 (d, 
2JC,F = 22.1 Hz, C=O), 141.6 
(ph-1C), 128.6 (ph-3,5C), 127.4 (ph-2,6C), 127.1 (ph-4C), 86. 9 (d, 1JC,F = 181.5 Hz, CHF), 73.9 
(benzh.-CH), 51.8 (NCH2), 51.2 (prz-2,6C), 48.2 (prz-3,5C), 26.6 (d, 
2JC,F = 22.1 Hz, CHFCH2). 
19F NMR (DMSO-d6, 282 MHz): δ –186.28 (CHF). HRMS (m/z): [M+H]
+ calcd. for 
C21H25FN2O2, 357.1978; found, 357.1980. HPLC (analytical Chromolith column (RP-18e, 100-
4.6 mm), 3 ml/min, methanol (0.1% trifluoroacetic acid) 20–60% in 8 min) RT: 5.2 min; purity: 
99.62%. 
Methyl 2-fluoro-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoate (25). 
Diphenyl(piperidin-4-yl)methanol hydrochloride (1.1 g, 3.6 mmol) was dissolved in DMSO (25 
ml). TEA (1 ml, 7.2 mmol) and compound 20 (1.4 g, 4.8 mmol) were subsequently added. The 
mixture was stirred overnight at 60 °C. After cooling the product was extracted into DCM and 
purified by column chromatography (TEA; DCM: methanol = 99: 1) giving a light yellow oil 
(0.35 g, 25%). 1H NMR (DMSO-d6, 600 MHz): δ 7.49 (d, J = 8.2 Hz, 4H, ph-2,6H), 7.25 (t, J = 
7.7 Hz, 4H, ph-3,5H), 7.12 (t, J = 7.3 Hz, 2H, ph-4H), 5.27 (s, 1H, OH), 5.16/5.08 (t/t, J = 
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 5.4/5.4 Hz, 0.5H/0.5H, CHF), 3.67 (s, 3H, CH3), 2.82-2.76 (m, 2H, pip-2,6H
eq), 2.45 (t, J = 11.9 
Hz, 1H, pip-4H), 2.36-2.30 (m, 2H, NCH2), 1.98-1.85 (m, 4H, CH2CHF, pip-2,6H
ax), 1.44-1.39 
(pip-3,5Heq), 1.25 (d, J = 12.0 Hz, 2H, pip-3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 170.0 (d, 
2JC,F = 23.6 Hz, C=O), 147.3 (ph-1C), 127.8 (ph-3-5C), 125.8 (ph-2,6C), 87.1 (d, 
1JC,F = 179.7 
Hz, CHF), 78.5 (COH), 55.0 (NCH2), 53.5 (pip-2,6C), 52.1 (CH3), 43.4 (pip-4C), 29.4 (d, 
2JC,F = 
20.6 Hz, CHFCH2), 26.0 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –193.29 (CHF). HRMS 
(m/z): [M+H]+ calcd. for C23H28FNO3, 386.2131; found, 386.2121. 
2-Fluoro-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-ol (26). Compound 25 (0.2 
g, 0.52 mmol) in THF (5 ml) was added dropwise to a suspension of lithium aluminium hydride 
(75 mg, 1.95 mmol) in THF (5 ml). After stirring for 1 h at room temperature the solution was 
quenched with brine and concentrated to dryness. The crude mixture was taken up in aqueous 
NaOH (2 N) and the product was extracted into DCM. Concentration gave the product as a white 
solid, which was purified by column chromatography (TEA; DCM: methanol = 9: 1); (0.15 g, 
83%). Mp: 144 °C. 1H NMR (DMSO-d6, 600 MHz): δ 7.50 (d, J = 8.2 Hz, 4H, ph-2,6H), 7.25 (t, 
J = 7.5 Hz, 4H, ph-3,5H), 7.12 (t, J = 7.3 Hz, 2H, ph-4H), 5.26 (s, 1H, OH), 5.00 (br s, 1H, 
CH2OH), 4.56-4.52/4.48-4.44 (m/m, 0.5H/0.5H, CHF), 3.54-3.41 (m, 2H, CH2OH), 2.86 (br s, 
2H, pip-2,6Heq), 2.46 (t, J = 11.6 Hz, 1H, pip-4H), 2.33 (br s, 2H, NCH2), 1.93-1.87 (m, 2H, pip-
2,6Hax), 1.74-1.64 (CH2CHF), 1.50-1.42 (pip-3,5H
eq), 1.25 (br s, 2H, pip-3,5Hax). 13C NMR 
(DMSO-d6, 150 MHz): δ 147.3 (ph-1C), 127.8 (ph-3-5C), 125.8 (ph-2,6C), 93.3 (d, 
1JC,F = 167.6 
Hz, CHF), 78.5 (COH), 64.0 (d, 2JC,F = 21.8 Hz, CH2OH), 53.8 (pip-2,6C), 53.3 (NCH2), 43.4 
(pip-4C), 28.5 (d, 2JC,F = 22.8 Hz, CH2CHF), 25.9 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): 
δ –186.46 (CHF). HRMS (m/z): [M+H]+ calcd. for C22H28FNO2, 358.2182; found, 358.2170.  
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 2-Fluoro-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (27). Compound 26 
(0.1 g, 0.28 mmol) was dissolved in DCM (5 ml). TEA (43 μl, 0.3 mmol) and acetic anhydride 
(35 μl, 0.3 mmol) were added under cooling (ice bath). The mixture was stirred 3 h at room 
temperature and subsequently quenched with aqueous NaOH (2 N). The organic layer was dried 
(MgSO4), filtered and purified by column chromatography (TEA; DCM: methanol = 95: 5). The 
product was isolated as colorless oil (0.11 g, quantitative conversion). 1H NMR (DMSO-d6, 600 
MHz): δ 7.49 (d, J = 7.9 Hz, 4H, ph-2,6H), 7.25 (t, J = 7.3 Hz, 4H, ph-3,5H), 7.11 (t, J = 7.6 Hz, 
2H, ph-4H), 5.26 (s, 1H, OH), 4.80-4.77/4.72-4.68 (m/m, 0.5H/0.5H, CHF), 4.23-4.08 (m, 2H, 
CH2OAc), 2.86-2.81 (m, 2H, pip-2,6H
eq), 2.46 (t, J = 11.8 Hz, 1H, pip-4H), 2.37-2.30 (m, 2H, 
NCH2), 2.04 (s, 3H, COCH3), 1.91-1.69 (m, 4H, CH2CHF, pip-2,6H
ax), 1.49-1.44 (pip-3,5Heq), 
1.21 (br s, 2H, pip-3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 170.2 (C=O), 147.3 (ph-1C), 
127.8 (ph-3-5C), 125.8 (ph-2,6C), 90.6 (d, 1JC,F = 168.9 Hz, CHF), 78.5 (COH), 65.4 (d, 
2JC,F = 
20.4 Hz, CH2OAc), 54.0 (NCH2), 53.3 (pip-2,6C), 43.5 (pip-4C), 28. 2 (d, 
2JC,F = 20.3 Hz, 
CH2CHF), 26.0 (pip-3,5C), 20.6 (COCH3). 
19F NMR (DMSO-d6, 282 MHz): δ –186.72 (CHF). 
HRMS (m/z): [M+H]+ calcd. for C24H30FNO3, 400.2288; found, 400.2286. 
2-Fluoro-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butanoic acid (28). Compound 25 
(0.13 g, 0.34 mmol) was dissolved in methanol (0.5 ml) and THF (0.5 ml). Aqueous potassium 
hydroxide (2 M, 1 ml) was added and the mixture was stirred overnight at room temperature. The 
organic solvents were subsequently evaporated and the aqueous solution neutralized with 
hydrogen chloride solution. The product precipitated as a white solid that was recrystallized from 
acetonitrile under addition of a drop of water (0.03 g, 24%). Mp: 242–244 °C (carbonisation). 1H 
NMR (DMSO-d6, 600 MHz): δ 7.43 (d, J = 7.7 Hz, 4H, ph-2,6H), 7.21 (t, J = 7.7 Hz, 4H, ph-
3,5H), 7.07 (t, J = 7.3 Hz, 2H, ph-4H), 5.23 (s, 1H, OH), 4.92/4.84 (s/s, 0.5H/0.5H, CHF), 3.43 
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 (br s, 2H, pip-2,6Heq), 3.13-3.04 (m, 2H, NCH2), 2.91 (m, 2H, pip-2,6H
ax), 2.74 (s, 1H, pip-4H), 
2.31-2.10 (CH2CHF), 1.49/1.25 (overlay with CD3COOD peak: pip-3,5H2). 
13C NMR (DMSO-
d6, 150 MHz): δ 171.0 (C=O), 146.0 (ph-1C), 127.8 (ph-3,5C), 126.0 (ph-4C), 125.5 (ph-2,6C), 
86.8 (d, 1JC,F = 181.8 Hz, CHF), 77.9 (COH), 51.8 (pip-2,6C, NCH2), 40.5 (pip-4C), 26.6 (d, 
2JC,F = 21.6 Hz, CH2CHF), 23.8 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –187.15 (CHF). 
HRMS (m/z): [M+H]+ calcd. for C22H26FNO3, 372.1975; found, 372.1984. 
tert-Butyl 4-(bis(4-fluorophenyl)(hydroxy)methyl)piperidine-1-carboxylate (33). To a 
cooled (ice bath) solution of 4-fluorophenylmagnesium bromide in THF (1 M, 8.75 ml) was 
added di-tert-butyl piperidine-1,4-dicarboxylate (0.5 g, 2.0 mmol), dissolved in anhydrous THF 
(10 ml). The mixture was heated to 60 °C for 3 h. After quenching with brine at 0 °C (ice bath) 
the mixture was concentrated to dryness. The crude product was taken up in water and extracted 
into ethyl acetate. The organic layer was dried (MgSO4), filtered and concentrated to give a light 
yellow solid. Recrystallization from ethanol gave a white solid (0.38 g, 47%). Mp: 152–152 °C. 
1H NMR (CDCl3, 300 MHz): δ 7.42-7.37 (m, 2H, ph-2,6H), 7.01-6.96 (m, 2H, ph-3,5H), 4.15 
(br s, 2H, pip-2,6Heq), 2.69 (t, J = 10.2 Hz, 2H, pip-2,6Hax), 2.51-2.42 (m, 1H, pip-4H), 1.50 (br 
s, 2H, pip-3,5Heq), 1.42 (s, 9H, C(CH3)3), 1.34-1.21 (m, 2H, pip-3,5H
ax). 13C NMR (CDCl3, 125 
MHz): δ 161.7 (d, 1JC,F = 244.5 Hz, ph-4C), 154.8 (C=O), 141.3 (ph-1C), 127.6 (d,
 3JC,F = 7.8 
Hz, ph-2,6C), 115.2 (d, 2JC,F = 21.0 Hz, ph-3,5C), 79.6 (COH), 79.2 (C(CH3)3), 44.6 (pip-4C), 
43.9 (pip-2,6C), 28.5 (C(CH3)3), 26.5 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –117.77 
(ph-F). HRMS (m/z): [M+H]+ calcd. for C23H27F2NO3, 402.1881; found, 402.1898. 
(4-Fluorophenyl)(phenyl)(piperidin-4-yl)methanol hydrochloride (34). To a solution of 
compound 32 (0.56 g, 1.46 mmol) in THF (1.0 ml) was added HCl in dioxane (4 M, 0.8 ml). The 
solution was stirred overnight at room temperature, while the product slowly crystallized as 
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 hydrochloric salt. The precipitate was filtered off and washed with THF and diethyl ether to give 
the product as a white solid (0.32 g, 68%). Mp: 240–242 °C. 1H NMR (DMSO-d6, 500 MHz): δ 
9.20/8.54 (br s/br s, 1H/1H, NH2
+), 7.53-7.48 (m, 4H, ph-2,6H, ph’-2,6H), 7.28 (t, J = 7.7 Hz, 
2H, ph-3,5H), 7.14 (t, J = 7.3 Hz, 2H, ph-4H), 7.09 (t, J = 8.8 Hz, 2H, ph’-3,5H), 5.66 (COH), 
3.19 (d, J = 12.0 Hz, 2H, pip-2,6Heq), 2.84 (br s, 3H, pip-2,6Hax, pip-4H), 1.64-1.56 (m, 2H, pip-
3,5Hax), 1.37 (t, J = 10.5, 2H, pip-3,5Heq). 13C NMR (CDCl3, 125 MHz): δ 160.6 (d, 
1JC,F = 241.4 
Hz, ph’-4C), 146.4 (ph-1C), 142.8 (ph’-1C), 128.0 (ph-3,5C), 127.8 (d, 3JC,F = 7.9 Hz, ph’-2,6C), 
126.2 (ph-4C), 125.7 (ph-2,6C), 114.5 (d, 2JC,F = 20.9 Hz, ph’-3,5C), 78.2 (COH), 43.2 (pip-
2,6C), 40.9 (pip-4C), 23.3 (pip-3,5C). 19F NMR (DMSO-d6, 282 MHz): δ –117.66 (ph-F). 
HRMS (m/z): [M+H]+ calcd. for C18H20FNO, 286.1607; found, 286.1594. 
Bis(4-fluorophenyl)(piperidin-4-yl)methanol hydrochloride (35). Compound 33 (0.5 g, 1.2 
mmol) was dissolved in THF (2 ml). HCl in dioxane (4 M, 0.6 ml) was added dropwise and the 
solution was stirred overnight at room temperature. During this time a white precipitate formed, 
which was filtered off, washed with DCM and diethyl ether and dried (0.24 g, 60%). Mp: 244 
°C. 1H NMR (DMSO-d6, 500 MHz): δ 9.16/8.52 (d/d, J = 9.7/9.7 Hz, 1H/1H, NH2
+), 7.51-7.49 
(m, 4H, ph-2,6H), 7.10 (t, J = 8.8 Hz, 4H, ph-3,5H), 5.73 (s, 1H, COH), 3.19 (d, J = 12.0 Hz, 2H, 
pip-2,6Heq), 2.84-2.82 (m, 3H, pip-2,6Hax, pip-4H), 1.61-1.54 (m, 2H, pip-3,5Hax), 1.38 (d, J = 
13.5 Hz, 2H, pip-3,5Heq). 13C NMR (DMSO-d6, 125 MHz): δ 160.6 (d, 
1JC,F = 241.4 Hz, ph-4C), 
142.6 (ph-1C), 127.8 (d, 3JC,F = 7.8 Hz, ph-2,6C), 114.6 (d, 
2JC,F = 20.9 Hz, ph-3,5C), 78.0 
(COH), 43.2 (pip-2,6C), 40.9 (pip-4C), 23.3 (pip-3,5C). 19F NMR (DMSO-d6, 282 MHz): δ: –
117.47 (ph-F). HRMS (m/z): [M+H]+ calcd. for C18H19F2NO, 304.1513; found, 304.1516.  
4-(4-((4-Fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)butyl acetate (38). Under 
inert atmosphere, compound 34 (0.1 g, 0.31 mmol), 4-bromobutyl acetate (0.09 ml, 0.62 mmol) 
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 and potassium carbonate (0.13 g, 0.93 mmol) were dissolved in anhydrous acetone (5 ml). After 
heating at 60 °C for 3 h the mixture was stirred overnight at room temperature. The inorganic 
compounds were filtered off and the crude purified by column chromatography (DCM: methanol 
= 100: 0  95: 5). The product was isolated as colorless oil (117 mg, 94%). 1H NMR (DMSO-
d6, 600 MHz): δ 7.53-7.48 (m, 4H, ph-2,6C, ph’-2,6C), 7.27 (t, J = 7.8 Hz, 2H, ph-3,5H), 7.13 (t, 
J = 7.3 Hz, 1H, ph-4H), 7.07 (d, J = 8.9 Hz, 2H, ph’-3,5H), 5.37 (s, 1H, COH), 3.98 (t, J = 6.5 
Hz, 2H, but-1H2), 2.90 (br s, 2H, pip-2,6H
eq), 2.50 (br s, 1H, pip-4H), 2.31 (br s, 2H, but-4H2), 
1.98 (m, 5H, CH3, pip-2,6H
ax), 1.56-1.46 (m, 6H, but-2,3H2, pip-3,5H
eq), 1.24 (br s, 2H, pip-
3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 170.5 (C=O), 160.5 (d, 
1JC,F = 240.8 Hz, ph’-4C), 
147.0 (ph-1C), 143.4 (ph’-1C), 127.9 (ph-3,5C), 127.8 (d, 3JC,F = 7.7 Hz, ph’-2,6C), 126.0 (ph-
4C), 125.7 (ph-2,6C), 114.1 (d, 2JC,F = 20.9 Hz, ph’-3,5C), 78.2 (COH), 63.8 (but-1C), 57.3 (but-
4C), 53.4 (pip-2,6C), 43.3 (pip-4C), 26.0 (but-2C), 25.7 (pip-3,5C), 22.6 (but-3C), 20.8 (CH3). 
19F NMR (DMSO-d6, 282 MHz): δ: –118.01 (ph’-F). HRMS (m/z): [M+H]
+ calcd. for 
C24H30FNO3, 400.2288; found, 400.2296.  
4-(4-((4-Fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)butan-1-ol (39). Under 
inert atmosphere, compound 34 (0.1 g, 0.31 mmol), 4-bromo-1-butanol (0.1 g, 0.62 mmol) and 
potassium carbonate (0.13 g, 0.93 mmol) were dissolved in anhydrous acetone (5 ml). After 
heating at 60 °C for 3 h the mixture was stirred overnight at room temperature. The inorganic 
compounds were filtered off and the crude purified by column chromatography (DCM: methanol 
= 98: 2  95: 5). The product was isolated as colorless oil (87 mg, 78%). 1H NMR (DMSO-d6, 
600 MHz): δ 7.53-7.48 (m, 4H, ph-2,6C, ph’-2,6C), 7.29 (t, J = 7.7 Hz, 2H, ph-3,5H), 7.15 (t, J 
= 7.3 Hz, 1H, ph-4H), 7.10 (d, J = 8.8 Hz, 2H, ph’-3,5H), 5.56 (s, 1H, COH), 3.56 (s, 1H, 
CH2OH), 3.39 (t, J = 6.3 Hz, 2H, but-1H2), 3.33 (pip-2,6H
eq, overlay with water), 3.19 (br s, 2H, 
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 pip-2,6Hax), 2.68 (br s, 3H, but-4H2, pip-4H), 1.59-1.55 (m, 4H, but-3H2, pip-3,5H
eq), 1.43-1.34 
(m, 4H, but-2H2, pip-3,5H
ax),. 13C NMR (DMSO-d6, 150 MHz): δ 160.6 (d, 
1JC,F = 241.1 Hz, 
ph’-4C), 146.6 (ph-1C), 143.0 (ph’-1C), 128.0 (ph-3,5C), 127.8 (d, 3JC,F = 7.8 Hz, ph’-2,6C), 
126.2 (ph-4C), 125.7 (ph-2,6C), 114.5 (d, 2JC,F = 20.9 Hz, ph’-3,5C), 78.1 (COH), 60.3 (but-1C), 
56.8 (but-4C), 53.5 (pip-2,6C), 41.9 (pip-4C), 29.9 (but-2C), 24.7 (pip-3,5C), 21.6 (but-3C). 19F 
NMR (DMSO-d6, 282 MHz): δ –117.74 (ph’-F). HRMS (m/z): [M+H]
+ calcd. for C22H28FNO2, 
358.2182; found, 358.2185. 
1-(3-(1,3-Dioxolan-2-yl)propyl)-4-((4-fluorophenyl)(phenyl)methylene)piperidine (41). 
Under inert atmosphere, compound 36 (0.14 g, 0.53 mmol), 2-(3-chloropropyl)-1,3-dioxolane 
(0.15 ml, 1.06 mmol), potassium carbonate (0.3 g, 2.1 mmol) and potassium iodide (0.02 g, 0.1 
mmol) were dissolved in anhydrous acetonitrile (10 ml). The mixture was heated overnight at 80 
°C. After cooling, the inorganic compounds were filtered off and the crude purified by column 
chromatography (DCM: methanol = 100: 0  95: 5). The product was isolated as colorless oil 
(50 mg, 25%). 1H NMR (CDCl3, 600 MHz): δ 7.28 (t, J = 7.6 Hz, 2H, ph-3,5H), 7.20 (t, J = 7.3 
Hz, 1H, ph-4H), 7.10-7.06 (m, 4H, ph-2,6H, ph’-2,6H), 6.96 (t, J = 8.6 Hz, 2H, ph’-3,5H), 4.88 
(t, J = 4.1 Hz, 1H, diox-CH), 3.96/3.84 (t/t, J = 6.9/6.9 Hz, 2H/2H, diox-4,5H2), 2.51 (s, 4H, pip-
2,6H2), 2.40-2.39 (m, 6H, prop-1H2, pip-3,5H2), 1.67 (m, 4H, prop-2,3H2). 
13C NMR (CDCl3, 
150 MHz): δ 161.6 (d, 1JC,F = 243.0 Hz, ph’-4C), 142.4 (ph-1C), 138.4 (d, 
4JC,F = 3.0 Hz, ph’-
1C), 135.9 (C=C), 134.9 (C=Cpip-4C), 131.5 (d, 3JC,F = 7.5 Hz, ph’-2,6C), 129.9 (ph-2,6C), 128.2 
(ph-3,5C), 126.6 (ph-4C), 115.0 (d, 2JC,F = 21.0 Hz, ph’-3,5C), 104.5 (diox-CH), 65.0 (diox-
4,5C), 58.3 (prop-1C), 55.2 (pip-2,6C), 31.9 (pip-3,5C), 31.6 (prop-3C), 21.4 (prop-2C). 19F 
NMR (DMSO-d6, 282 MHz): δ –116.74 (ph’-F). HRMS (m/z): [M+H]
+ calcd. for C24H28FNO2, 
382.2182; found, 382.2175. 
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 4-(4-((4-Fluorophenyl)(phenyl)methylene)piperidin-1-yl)butanal (42). Compound 41 (30 
mg, 0.08 mmol) was dissolved in THF (0.5 ml) and HCl (1 M; 1.5 ml), and the solution was 
stirred overnight at room temperature. The mixture was subsequently diluted with DCM and 
extracted with aqueous NaOH (2 M). The separated organic layer was dried (MgSO4), filtered 
and concentrated under reduced pressure to yield the product as colorless oil (20 mg, 74%). 1H 
NMR (CDCl3, 600 MHz): δ 9.71 (CHO), 7.28 (t, J = 7.6 Hz, 2H, ph-3,5H), 7.20 (t, J = 7.4 Hz, 
1H, ph-4H), 7.10-7.06 (m, 4H, ph-2,6H, ph’-2,6H), 6.96 (t, J = 8.6 Hz, 2H, ph’-3,5H), 2.50 (br s, 
4H, pip-2,6H2), 2.40 (br s, 6H, but-4H2, pip-3,5H2), 1.60 (m, 4H, but-2,3H2). 
13C NMR (CDCl3, 
150 MHz): δ 201.4 (CHO), 161.6 (d, 1JC,F = 245.3 Hz, ph’-4C), 142.4 (ph-1C), 138.4 (ph’-1C), 
136.1 (C=C), 134.8 (C=Cpip-4C), 131.4 (d, 3JC,F = 7.8 Hz, ph’-2,6C), 129.9 (ph-2,6C), 128.2 (ph-
3,5C), 126.6 (ph-4C), 115.0 (d, 2JC,F = 21.1 Hz, ph’-3,5C), 55.3 (but-4C), 52.9 (pip-2,6C), 31.6 
(but-2C), 30.6 (pip-3,5C), 22.1 (but-3C). 19F NMR (DMSO-d6, 282 MHz): δ –116.53 (ph’-F). 
HRMS (m/z): [M+H]+ calcd. for C22H24FNO, 338.1920; found, 338.1912. 
4-(4-((4-Fluorophenyl)(phenyl)methylene)piperidin-1-yl)butanoic acid (44). Compound 43 
(0.3 g, 0.8 mmol) was dissolved in methanol (1 ml) and THF (1 ml). Aqueous potassium 
hydroxide (2 M, 2 ml) was added and the mixture was stirred for 3 h at room temperature. The 
organic solvents were subsequently removed under reduced pressure and the aqueous solution 
neutralized with hydrogen chloride solution. An oily product separating from the mixture was 
extracted into DCM. The dried and concentrated product was purified by column 
chromatography (DCM: methanol = 97: 3  7: 3) and isolated as white solid (0.1 g, 36%). Mp: 
115–117 °C. 1H NMR (DMSO-d6, 600 MHz): δ 7.32 (t, J = 7.6 Hz, 2H, ph-3,5H), 7.23 (t, J = 7.4 
Hz, 1H, ph-4H), 7.16-7.09 (m, 6H, ph-2,6H, ph’-2,3,5,6H), 2.60 (br s, 4H, pip-2,6H2), 2.27 (t, J 
= 7.0 Hz, 2H, but-4H2), 2.30 (t, J = 5.5 Hz, 4H, pip-3,5H2), 2.26 (t, J = 7.1 Hz, 2H, but-2H2), 
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 1.72-1.67 (m, 2H, but-3H2). 
13C NMR (DMSO-d6, 150 MHz): δ 174.4 (C=O), 160.9 (d, 
1JC,F = 
242.0, ph’-4C), 141.8 (ph-1C), 138.2 (d, 4JC,F = 3.2 Hz, ph’-1C), 134.7 (C=C), 134.5 (C=C
pip-4C), 
131.3 (d, 3JC,F = 8.0 Hz, ph’-2,6C), 129.4 (ph-3,5C), 128.3 (ph-2,6C), 126.7 (ph-4C), 115.1 (d, 
2JC,F = 21.2 Hz, ph’-3,5C), 56.5 (but-4C), 54.0 (pip-2,6C), 32.1/21.3 (but-2,3C), 30.4 (pip-3,5C). 
19F NMR (DMSO-d6, 282 MHz): δ –116.35 (ph’-F). HRMS (m/z): [M+H]
+ calcd. for 
C22H24FNO2, 354.1864; found, 354.1863. 
Ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate (47). Under inert atmosphere, 
compound 37 (as HCl salt; 0.25 g, 1.0 mmol), 4-bromo-butyric acid ethyl ester (0.28 ml, 2.0 
mmol) and potassium carbonate (0.57 g, 4.0 mmol) were dissolved in anhydrous acetone (10 ml). 
After heating at 60 °C for 3 h the mixture was stirred overnight at room temperature. The 
inorganic compounds were filtered off and the crude purified by column chromatography (DCM: 
methanol = 100: 0  96: 4). The product was isolated as colorless oil (0.28 g, 88%). An 
analytical sample of the product was crystallized as HCl salt. Mp: 138–139 °C. 1H NMR 
(DMSO-d6, 600 MHz): δ 10.67 (br s, 1H, NH
+), 8.11-8.09 (dd, J = 8.7 Hz, 2H, ph-2,6H), 7.40 
(dd, J = 8.8 Hz, 2H, ph-3,5H), 4.08 (q, 2H, OCH2CH3), 3.72 (m, 1H, pip-4H), 3.52 (d, J = 11.8 
Hz, 2H, pip-2,6Heq), 3.08-3.02 (m, 4H, pip-2,6Hax, but-4H2), 2.42 (t, J = 7.4 Hz, 2H, but-2H2), 
2.00-1.92 (m, 6H, pip-3,5H2, but-3H2), 1.20 (t, J = 7.1 Hz, 3H, OCH2CH3). 
13C NMR (DMSO-
d6, 150 MHz): δ 199.6 (C=O
ketone), 172.0 (C=Oester), 165.2 (d, 1JC,F = 250.7 Hz, ph-4C), 131.9 (d, 
4JC,F = 2.7, ph-1C), 131.4 (d, 
3JC,F = 9.3, ph-2,6C), 116.01 (d, 
2JC,F = 21.8, ph-3,5C), 60.1 
(OCH2CH3), 55.2 (but-4C), 52.4 (pip-2,6C), 30.6 (but-2C), 25.6 (pip-3,5C), 18.7 (but-3C), 14.2 
(OCH2CH3). 
19F NMR (DMSO-d6, 282 MHz): δ –106.04 (ph’-F). HRMS (m/z): [M+H]
+ calcd. 
for C18H24FNO2, 322.1818; found, 322.1813. 
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 2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethyl 4-methylbenzenesulfonate (48). 2-(2,2-Dimethyl-
[1,3]dioxolan-4-yl)-ethanol (5 g, 34 mmol) was dissolved in DCM (100 ml). The solution was 
cooled (ice bath) and pyridine (3 ml, 37.4 mmol) and tosyl chloride (7.1 g, 37.4 mmol) were 
subsequently added. The mixture was stirred overnight at room temperature. After dilution with 
DCM the reaction was quenched with water. The separated organic layer was washed with brine, 
dried (MgSO4) and concentrated to dryness. The product was purified by column 
chromatography (DCM) giving a colorless oil (2.8 g, 27.5%). 1H NMR (DMSO-d6, 600 MHz): δ 
7.78 (d, J = 8.3 Hz, 2H, ph-2,6H), 7.35 (d, J = 7.5 Hz, 2H, ph-3,5H), 4.19-4.09 (m, 3H, diox-
CH2, diox-4H), 4.01/3.51 (t/t, J = 4.7/5.0 Hz, 1H/1H, diox-5H2), 2.45 (s, 3H, ph-CH3), 1.94-1.86 
(m, 2H, OCH2), 1.33/1.28 (s/s, 3H/3H, C(CH3)2). 
13C NMR (DMSO-d6, 150 MHz): δ 145.0 (ph-
4C), 133.0 (ph-1C), 130.1 (ph-3,5C), 128.1 (ph-2,6C), 109.2 (C(CH3)2), 72.4 (diox-4C), 69.2 
(diox-5C), 67.5 (O-CH2), 33.2 (diox-CH2), 27.0/25.7 (C(CH3)2), 21.8 (ph-CH3). HRMS (m/z): 
[M+H]+ calcd. for C14H20O5S, 301.1110; found, 301.1113. 
1-Benzhydryl-4-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)piperazine (49). TEA (1.24 ml, 
9.3 mmol) was dissolved in dry acetonitrile (100 ml). Under inert atmosphere, 1-benzhydryl-
piperazine (2.3 g, 9.3 mmol) and compound 48 (2.8 g, 9.3 mmol) were subsequently added. The 
solution was stirred for 6 h at 70 °C. After cooling it was concentrated to dryness and the product 
was purified by column chromatography (TEA; DCM: methanol = 100: 0  95: 5) giving a 
yellow oil (1.36 g, 39%). 1H NMR (DMSO-d6, 600 MHz): δ 7.40 (d, J = 7.7 Hz, 4H, ph-2,6H), 
7.27 (t, J = 7.7 Hz, 4H, ph-3,5H), 7.17 (t, J = 7.4 Hz, 2H, ph-4H), 4.23 (s, 1H, benzh.-CH), 4.02-
3.98 (m, 1H, diox-4H), 3.97/3.42 (t/t, J = 4.6/7.4 Hz, 1H/1H, diox-5H2), 2.49-2.24 (m, 10H, prz-
2,3,5,6H2, NCH2), 1.63-1.59 (m, 2H, OCH2), 1.28/1.23 (s/s, 3H/3H, C(CH3)2). 
13C NMR 
(DMSO-d6, 150 MHz): δ 143.0 (ph-1C), 128.5 (ph-3,5C), 127.6 (ph-2,6C), 126.8 (ph-4C), 107.7 
Page 44 of 104
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 (C(CH3)2), 75.3 (benzh.-CH), 74.2 (diox-4C), 68.8 (diox-5C), 55.0 (NCH2), 53.0 (prz-2,6C), 
51.6 (prz-3,5C), 30.6 (diox-CH2), 26.9/25.7 (C(CH3)2). HRMS (m/z): [M+H]
+ calcd. for 
C24H32N2O2, 381.2542; found, 381.2550. 
4-(4-Benzhydrylpiperazin-1-yl)butane-1,2-diol (50). Compound 49 (1.36 g, 3.6 mmol) was 
dissolved in methanol (13 ml). PTSA (1.5 g, 7.9 mmol) was added and the solution was stirred 
for 4 h at 40 °C. After cooling it was quenched with aqueous NaOH (2 N). The organic solvent 
was removed under reduced pressure and the crude product extracted in DCM. Final purification 
was performed by column chromatography (TEA; DCM: methanol = 95: 5  90: 10) giving the 
product as colorless oil (1.1 g, 90%). 1H NMR (DMSO-d6, 600 MHz): δ 7.40 (d, J = 7.6 Hz, 4H, 
ph-2,6H), 7.28 (t, J = 7.7 Hz, 4H, ph-3,5H), 7.17 (t, J = 7.4 Hz, 2H, ph-4H), 4.64/4.60 (br s/br s, 
2H, OH/OH), 4.24 (s, 1H, benzh.-CH), 3.46-3.42 (m, 1H, CHOH), 3.28-3.25/3.21-3.16 (m/m, 
1H/1H, CH2OH), 2.43-2.30 (m, 10H, prz-2,3,5,6H2, NCH2), 1.61-1.56/1.40-1.42 (m/m, 2H, 
CH2CH). 
13C NMR (DMSO-d6, 150 MHz): δ 143.0 (ph-1C), 128.55 (ph-3,5C), 127.57 (ph-
2,6C), 126.85 (ph-4C), 75.24 (benzh.-CH), 70.46 (CHOH), 65.9 (CH2OH), 55.0 (NCH2), 53.0 
(prz-2,6C), 51.6 (prz-3,5C), 30.7 (CH2CH). HRMS (m/z): [M+H]
+ calcd. for C21H28N2O2, 
341.2229; found, 341.2226. 
4-(4-Benzhydrylpiperazin-1-yl)-2-hydroxybutyl acetate (51). Compound 50 (1.5 g, 1.5 
mmol) was dissolved in DCM (20 ml). TEA (0.23 ml, 1.65 mmol) and acetic anhydride (0.14 ml, 
1.5 mmol) were added under cooling (ice bath). The mixture was stirred 3 h at room temperature 
and subsequently quenched by adding aqueous NaOH (2 N). The separated and washed (brine, 
water) organic layer was concentrated and purified by column chromatography (TEA; DCM: 
methanol = 97: 3) giving the product as colorless oil (0.26 g, 46%). 1H NMR (DMSO-d6, 600 
MHz): δ 7.41 (d, J = 7.5 Hz, 4H, ph-2,6H), 7.28 (t, J = 7.7 Hz, 4H, ph-3,5H), 7.17 (t, J = 7.3 Hz, 
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 2H, ph-4H), 5.02 (br s, 1H, OH), 4.24 (s, 1H, benzh.-CH), 3.87 (d, J = 5.6 Hz, 2H, 
CH2OCOCH3), 3.70-3.66 (m, 1H, CHOH), 2.52-2.09 (m, 10H, prz-2,3,5,6H2, NCH2), 1.99 (s, 
3H, COCH3), 1.58-1.51/1.46-1.38 (m/m, 2H, CH2CH). 
13C NMR (DMSO-d6, 150 MHz): δ 170.4 
(C=O), 143.0 (ph-1C), 128.5 (ph-3,5C), 127.6 (ph-2,6C), 126.9 (ph-4C), 75.2 (benzh.-CH), 68.0 
(CH2OCOCH3), 66.9 (CHOH), 54.5 (NCH2), 53.0 (prz-2,6C), 51.6 (prz-3,5C), 30.2 (CH2CH), 
21.1 (COCH3). HRMS (m/z): [M+H]
+ calcd. for C23H30N2O3, 383.2335; found, 383.2324. 
4-(4-Benzhydrylpiperazin-1-yl)-2-((methylsulfonyl)oxy)butyl acetate (52). Compound 51 
(1.3 g, 3.4 mmol) was dissolved in DCM (20 ml). TEA (0.5 ml, 3.7 mmol) and methanesulfonyl 
chloride (0.3 ml, 3.7 mmol) were added dropwise and under cooling (ice bath). The mixture was 
stirred 1 h at room temperature and subsequently quenched with aqueous NaOH (2 N). The 
separated, dried (MgSO4) and filtered organic layer was purified by column chromatography 
(TEA; DCM: methanol = 100: 0  97: 3). The product was isolated as colorless oil (1.1 g, 70%). 
1H NMR (DMSO-d6, 600 MHz): δ 7.41 (d, J = 8.0 Hz, 4H, ph-2,6H), 7.28 (t, J = 7.4, 4H, ph-
3,5H), 7.17 (t, J = 7.2 Hz, 2H, ph-4H), 4.84-4.80 (m, 1H, CHOMs), 4.25/4.14 (dd/dd, J = 
12.1/12.4 Hz, 1H/1H, CHCH2O), 4.25 (s, 1H, benzh.-CH), 3.18 (s, 3H, SCH3), 2.50-2.10 (m, 
10H, prz-2,3,5,6H2, NCH2), 2.03 (s, 3H, COCH3), 1.85-1.80 (m, 2H, CH2CH). 
13C NMR 
(DMSO-d6, 150 MHz): δ 170.1 (C=O), 143.0 (ph-1C), 128.6 (ph-3,5C), 127.6 (ph-2,6C), 126.9 
(ph-4C), 78.5 (CHOMs), 75.3 (benzh.-CH), 64.7 (CH2O), 55.0 (NCH2), 52.6 (prz-2,6C), 51.6 
(prz-3,5C), 37.7 (SCH3), 27.9 (CH2CH), 20.6 (COCH3). HRMS (m/z): [M+H]
+ calcd. for 
C24H32N2O5S, 461.2110; found, 461.2086. 
(1-(2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethyl)piperidin-4-yl)diphenylmethanol (53). TEA (4 
ml, 29.3 mmol) was dissolved in dry acetonitrile (50 ml). Under inert atmosphere, 
diphenyl(piperidin-4-yl)methanol hydrochloride (8.64 g, 24.1 mmol) and compound 48 (7.2 g g, 
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 24.1 mmol) were subsequently added. The solution was stirred for 6 h at 70 °C. After cooling it 
was concentrated to dryness and the product was purified by column chromatography (TEA; 
DCM: methanol = 100: 0  95: 5) giving a light yellow oil (1.5 g, 16%). 1H NMR (DMSO-d6, 
600 MHz): δ 7.50 (d, J = 8.2 Hz, 4H, ph-2,6H), 7.25 (t, J = 7.7 Hz, 4H, ph-3,5H), 7.11 (t, J = 7.3 
Hz, 2H, ph-4H), 5.23 (s, 1H, OH), 4.01-3.95 (m, 2H, diox-4H, diox-5H), 3.42 (t, J = 7.2 Hz, 1H, 
diox-5H2), 2.82 (br s, 2H, pip-2,6H
eq), 2.45 (t, J = 11.5 Hz, 1H, pip-4H), 2.28/2.24 (br s/br s, 2H, 
NCH2), 1.86-1.77 (m, 2H, pip-2,6H
ax), 1.62-1.60 (m, 2H, CH2CH), 1.47-1.43 (m, 2H, pip-
3,5Heq), 1.28/1.23 (s/s, 3H/3H, C(CH3)2), 1.22 (br s, 2H, pip-3,5H
ax). 13C NMR (DMSO-d6, 150 
MHz): δ 147.4 (ph-1C), 127.8 (ph-3-5C), 125.6 (ph-2,6C), 107.7 (C(CH3)2), 78.4 (COH), 75.0 
(diox-4C), 68.3 (diox-5C), 66.1 (NCH2), 53.6 (pip-2,6C), 43.6 (pip-4C), 35.2 (diox-CH2), 
26.9/25.8 (C(CH3)2), 25.9 (pip-3,5C). HRMS (m/z): [M+H]
+ calcd. for C25H33NO3, 396.2539; 
found, 396.2533. 
4-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)butane-1,2-diol (54). Compound 53 (1.5 g, 
3.9 mmol) was dissolved in methanol (15 ml). PTSA (1.1 g, 5.8 mmol) was added and the 
solution was stirred for 4 h at 40 °C. After cooling it was quenched with aqueous NaOH (2 N). 
The organic solvent was removed under reduced pressure and the crude product extracted in 
DCM. Final purification was performed by column chromatography (TEA; DCM: methanol = 
95: 5  90: 10) giving the product as colorless oil (1.35 g, quantitative conversion). 1H NMR 
(DMSO-d6, 300 MHz): δ 7.48 (d, J = 7.6 Hz, 4H, ph-2,6H), 7.24 (t, J = 7.6 Hz, 4H, ph-3,5H), 
7.10 (t, J = 7.2 Hz, 2H, ph-4H), 5.26 (s, 1H, OH), 4.78 (br s, 2H, 2x OH), 3.46-3.42 (m, 1H, 
CHOH), 3.29-3.15 (m, 2H, CH2OH), 2.88 (br s, 2H, pip-2,6H
eq), 2.49-2.34 (m, 3H, pip-4H, 
NCH2), 1.90 (br s, 2H, pip-2,6H
ax), 1.56-1.35 (m, 4H, CH2OH, pip-3,5H
eq), 1.25 (d, J = 12.2 Hz, 
2H, pip-3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 147.3 (ph-1C), 127.8 (ph-3-5C), 125.8 (ph-
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 2,6C), 78.5 (COH), 70.7 (CHOH), 65.9 (CH2OH), 55.3 (NCH2), 53.6 (pip-2,6C), 43.4 (pip-4C), 
30.4 (CH2CH(OH)CH2OH), 25.9 (pip-3,5C). HRMS (m/z): [M+H]
+ calcd. for C22H29NO3, 
356.2226; found, 356.2216. 
2-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate (55). Compound 54 
(1.35 g, 3.9 mmol) was dissolved in DCM (50 ml). TEA (0.6 ml, 4.3 mmol) and acetic anhydride 
(0.4 ml, 3.9 mmol) were subsequently added and the solution was stirred for 3 h at room 
temperature. The reaction was quenched with aqueous NaOH (2 N) and the organic layer was 
separated, dried (MgSO4), filtered and concentrated under reduced pressure. Final purification 
was performed by column chromatography (TEA; DCM: methanol = 99: 1  97: 3) giving the 
product as colorless oil (0.6 g, 41%). 1H NMR (DMSO-d6, 600 MHz): δ 7.50 (d, J = 8.2 Hz, 4H, 
ph-2,6H), 7.25 (t, J = 7.7 Hz, 4H, ph-3,5H), 7.11 (t, J = 7.2 Hz, 2H, ph-4H), 5.26 (s, 1H, COH), 
4.76 (br s, 1H, CHOH), 3.86 (d, J = 5.5 Hz, 2H, CH2OCOCH3), 3.71-3.67 (m, 1H, CHOH), 2.86 
(t, J = 13.9 Hz, 2H, pip-2,6Heq), 2.47 (t, J = 8.7 Hz, 1H, pip-4H), 2.39-2.31 (m, 2H, NCH2), 2.00 
(s, 3H, COCH3), 1.86 (t, J = 13.1 Hz, 2H, pip-2,6H
ax), 1.53-1.40 (m, 4H, CH2CH(OH), pip-
3,5Heq), 1.22 (d, J = 12.0 Hz, 2H, pip-3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 170.4 (C=O), 
147.3 (ph-1C), 127.8 (ph-3-5C), 125.8 (ph-2,6C), 78.5 (COH), 68.0 (CH2OCOCH3), 67.2 
(CHOH), 55.0 (NCH2), 53.7 (pip-2,6C), 43.5 (pip-4C), 30.1 (CH2CH(OH)CH2), 26.0 (pip-3,5C), 
20.8 (COCH3). HRMS (m/z): [M+H]
+ calcd. for C24H31NO4, 398.2331; found, 398.2331. 
4-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)-2-((methylsulfonyl)oxy)butyl acetate (56). 
To a cooled (ice bath) solution of compound 55 (0.32 g, 0.8 mmol) and TEA (0.12 ml, 0.88 
mmol) in DCM (10 ml) was added methanesulfonyl chloride (0.07 ml, 0.88 mmol) dropwise. 
The mixture was stirred 1 h at room temperature and subsequently quenched with brine. The 
separated, dried (MgSO4) and filtered organic layer was purified by column chromatography 
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 (TEA; DCM: methanol = 99: 1  98: 2). The product was isolated as colorless solid (0.1 g, 
26%). Mp: 78 °C. 1H NMR (DMSO-d6, 600 MHz): δ 7.50 (d, J = 8.0 Hz, 4H, ph-2,6H), 7.25 (t, J 
= 7.3 Hz, 4H, ph-3,5H), 7.11 (t, J = 7.3 Hz, 2H, ph-4H), 5.26 (s, 1H, OH), 4.83-4.79 (m, 1H, 
CHOMs), 4.27-4.12 (m, 2H, CH2OAc), 3.19 (s, 3H, SO2CH3), 2.84 (t, J = 13.3 Hz, 2H, pip-
2,6Heq), 2.46 (t, J = 11.9 Hz, 1H, pip-4H), 2.38-2.27 (m, 2H, NCH2), 2.03 (s, 3H, COCH3), 1.90-
1.73 (m, 4H, CH2CHF, pip-2,6H
ax), 1.47-1.44 (m, 2H, pip-3,5Heq), 1.21 (d, J = 12.0 Hz, 2H, pip-
3,5Hax). 13C NMR (DMSO-d6, 150 MHz): δ 170.1 (C=O), 147.3 (ph-1C), 127.8 (ph-3-5C), 125.7 
(ph-2,6C), 78.5 (COH), 64.7 (CH2OAc), 53.8 (NCH2), 53.1 (pip-2,6C), 43.5 (pip-4C), 37.7 
(SO2CH3), 28.1 (CH2CH(OMs)), 26.0 (pip-3,5C), 20.6 (COCH3). HRMS (m/z): [M+H]
+ calcd. 
for C25H33NO6S, 476.2107; found, 476.2088. 
Ethyl 4-(4-(4-(phenylthio)benzoyl)piperidin-1-yl)butanoate (63). Under inert atmosphere, 
compound 60 (0.26 g, 0.8 mmol), 4-bromo-butyric acid ethyl ester (0.22 ml, 1.6 mmol) and 
potassium carbonate (0.44 g, 3.2 mmol) were dissolved in anhydrous acetone (10 ml). After 
heating at 60 °C for 3 h the mixture was stirred overnight at room temperature. The inorganic 
compounds were filtered off and the crude purified by column chromatography (DCM: methanol 
= 100: 0  97: 3). The product was isolated as colorless oil (0.26 g, 79%). 1H NMR (CDCl3, 600 
MHz): δ 7.79 (d, J = 8.5 Hz, 2H, ph-2,6H), 7.50-7.49 (m, 2H, ph’-2,6H), 7.40-7.39 (m, 3H, ph’-
3-5H), 7.20 (d, J = 8.5 Hz, 2H, ph-3,5H), 4.12 (q, 2H, OCH2CH3), 3.18-3.15 (m, 1H, pip-4H), 
2.98 (d, J = 11.6 Hz, 2H, pip-2,6Heq), 2.40 (t, J = 7.2 Hz, 2H, but-4H2), 2.33 (t, J = 7.3 Hz, 2H, 
but-2H2), 2.11 (br s, 2H, pip-2,6H
ax), 1.85-1.80 (m, 6H, pip-3,5H2, but-3H2), 1.25 (t, J = 7.1 Hz, 
3H, OCH2CH3). 
13C NMR (CDCl3, 150 MHz): δ 201.7 (C=O
ketone), 173.7 (C=Oester), 144.9 (ph-
1C), 134.1 (ph-2,6C), 133.4 (ph-1C), 132.1 (ph’-1C), 129.91/129.89 (ph-3,5C, ph’-2,6C), 129.0 
(ph’-3,5C), 127.6 (ph’-4C), 60.5 (OCH2CH3), 57.8 (but-4C), 53.1 (pip-2,6C), 43.4 (pip-4C), 32.4 
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 (but-2C), 28.6 (pip-3,5C), 22.2 (but-3C), 14.4 (OCH2CH3). HRMS (m/z): [M+H]
+ calcd. for 
C24H30NO3S, 412.1946; found, 412.1936. 
(4-(1-(4-Ethoxy-4-oxobutyl)piperidine-4-carbonyl)phenyl)diphenylsulfonium 
trifluoromethanesulfonate (64). To a solution of compound 63 (0.3 g, 0.73 mmol) in 
chlorobenzene (3 ml) were added trifluoromethanesulfonic acid (65.0 µl, 0.73 mmol), 
diphenyliodonium triflate (0.31 g, 0.73 mmol) and copper(II) benzoate hydrate (11.5 mg, 0.036 
mmol) and the mixture was heated at 125 °C for 1 h. After cooling, the resulting brown oil was 
washed with diethyl ether (3 × 20 ml). The product was purified by column chromatography 
(DCM: methanol = 10: 0  9: 1). The isolated product was dissolved in DCM (5 ml) and washed 
with aqueous NaOH (2 M; 5 ml) and a saturated solution of sodium triflate (5 ml). The organic 
phase was dried (MgSO4), filtered and concentrated to give the product as a brown oil (0.37 g, 
79%). 1H NMR (DMSO-d6, 600 MHz): δ 8.27 (d, J = 8.5 Hz, 2H, ph-2,6H), 7.94 (d, J = 8.2 Hz, 
2H, ph-3,5H), 7.90-7.86 (m, 6H, ph’-2,4,6H), 7.81-7.78 (m, 4H, ph’-3,5H), 4.05 (q, 2H, 
OCH2CH3), 3.01/2.34/2.08/1.78 (v br s, 15H, pip-2,3,5,6H2, pip-4H, but-1-3H2), 1.19 (t, J = 7.1 
Hz, 3H, OCH2CH3). 
13C NMR (DMSO-d6, 150 MHz): δ 169.2 (C=O
ester), 134.6 (ph-1C), 131.7 
(ph’-3,5C), 131.6 (ph-3,5C), 131.5 (ph-2,6C), 130.1 (ph’-2,6C), 124.9 (ph-4C), 120.7 (q, 1JC,F = 
320.4 Hz, CF3), 59.9 (OCH2CH3), 14.2 (OCH2CH3). 
19F NMR (DMSO-d6, 282 MHz): δ –78.21 
(CF3). HRMS (m/z): [M]
+ calcd. for C30H34NO3S, 488.2259; found, 488.2242. 
1-(3-(1,3-Dioxolan-2-yl)propyl)-4-((4-((4-
methoxyphenyl)thio)phenyl)(phenyl)methylene)piperidine (73). Under inert atmosphere, 
compound 68 (0.42 g, 1.1 mmol), 2-(3-chloropropyl)-1,3-dioxolane (0.3 ml, 2.2 mmol), 
potassium carbonate (0.6 g, 4.4 mmol) and potassium iodide (37 mg, 0.22 mmol) were dissolved 
in anhydrous acetonitrile (10 ml). After heating at 80 °C for 5 h the mixture was stirred overnight 
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 at room temperature. The inorganic compounds were filtered off and the crude purified by 
column chromatography (DCM: methanol = 98: 2  8: 2). The product was isolated as colorless 
oil (0.13 g, 24%). 1H NMR (DMSO-d6, 600 MHz): δ 7.42 (d, J = 8.6 Hz, 2H, ph’’-2,6H), 7.30 (t, 
J = 7.6 Hz, 2H, ph-3,5H), 7.21 (t, J = 7.4 Hz, 1H, ph-4H), 7.06-7.04 (m, 4H, ph-2,6H, ph’-2,6H), 
7.01-6.99 (m, 4H, ph’-3,5H, ph’’-3,5H), 4.77 (t, J = 4.5 Hz, 2H, diox-CH), 3.85/3.74 (t/t, J = 
6.9/6.9 Hz, 2H/2H, diox-4,5H2), 3.75 (s, 3H, OCH3), 2.39-2.23 (m, 10H, pip-2,3,5,6H2, prop-
1H2), 1.56-1.50 (m, 4H, but-2,3H2). 
13C NMR (DMSO-d6, 150 MHz): δ 159.8 (ph’’-4C), 141.9 
(ph-1C), 139.7 (ph’-1C), 136.0 (ph’-4C, C=Cpip), 135.6 (ph’’-2,6C), 134.2 (C=Cpip), 130.3 (ph’-
3,5C), 129.4 (ph-2,6C), 128.2 (ph-3,5C), 127.2 (ph’-2,6C), 126.5 (ph-4C), 122.7 (ph’’-1C), 
115.4 (ph’’-3,5C), 103.5 (diox-CH), 64.2 (diox-4,5C), 57.2 (prop-1C), 55.3 (OCH3), 54.4 (pip-
2,6C), 31.2 (pip-3,5C), 30.6 (prop-3C), 21.1 (prop-2C). HRMS (m/z): [M+H]+ calcd. for 
C31H35NO3S, 502.2416; found, 502.2412. 
(4-((1-(3-(1,3-Dioxolan-2-yl)propyl)piperidin-4-ylidene)(phenyl)methyl)phenyl)bis(4-
methoxyphenyl)sulfonium trifluoromethanesulfonate (74). To a solution of compound 73 
(120 mg, 0.24 mmol) in chlorobenzene (1.0 ml) were added trifluoromethanesulfonic acid (21.5 
µl, 0.24 mmol), compound 75 (120 mg, 0.24 mmol) and copper(II) benzoate (4 mg, 0.01 mmol) 
and the mixture was heated at 125 °C for 1 h. After cooling, the resulting brown oil was washed 
with diethyl ether (3 × 5 ml). The product was purified by column chromatography (DCM: 
methanol = 10: 0  9: 1). The isolated product was dissolved in DCM (5 ml) and washed with 
aqueous NaOH (2 M; 5 ml) and a saturated solution of sodium triflate (5 ml). The organic phase 
was dried (MgSO4), filtered and concentrated to give the product as a light yellow oil (50 mg, 
28%). 1H NMR (DMSO-d6, 600 MHz): δ 7.67 (d, J = 8.9 Hz, 2H, ph-2,6H), 7.49 (d, J = 8.3 Hz, 
2H, ph’-2,6H), 7.39 (d, J = 8.4 Hz, 2H, ph’-3,5H), 7.30 (t, J = 7.5 Hz, 2H, ph’’-3,5H), 7.23 (t, J 
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 = 7.4 Hz, 1H, ph’’-4H), 7.17 (d, J = 8.9 Hz, 4H, ph-3,5H), 7.07 (d, J = 7.7 Hz, 2H, ph’’-2,6H), 
4.87 (t, J = 4.3 Hz, 2H, diox-CH), 3.95/3.84 (t/t, J = 6.9/6.9 Hz, 2H/2H, diox-4,5H2), 3.90 (s, 6H, 
OCH3), 2.53-2.51 (m, 4H, pip-2,6H2), 2.43-2.40 (m, 2H, prop-1H2), 2.37 (s, 4H, pip-3,5H2), 
1.68-1.60 (m, 4H, prop-2,3H2). 
13C NMR (DMSO-d6, 150 MHz): δ 164.6 (ph-4C), 148.7 (ph’-
1C), 141.0/139.1 (ph’-4C, ph’’-1C), 133.6/123.5 (C=Cpip), 133.2 (ph-2,6C), 132.8 (ph’-3,5C), 
130.0 (ph’-2,6C), 129.9 (ph’’-2,6C), 128.6 (ph’’-3,5C), 127.2 (ph’’-4C), 121.0 (q, 1JC,F = 318.0 
Hz, CF3), 117.3 (ph-3,5C), 114.4 (ph-1C), 104.4 (diox-CH), 65.0 (diox-4,5C), 58.1 (prop-1C), 
56.2 (OCH3), 55.0 (pip-2,6C), 31.9 (pip-3,5C), 31.7 (prop-3C), 21.4 (prop-2C). 
19F NMR 
(DMSO-d6, 282 MHz): δ –78.05 (CF3). HRMS (m/z): [M]
+ calcd. for C38H42NO4S, 608.2662; 
found, 608.2683. 
Radiochemistry – Equipment. All labeling reactions were performed manually using 
[18F]fluoride in [18O]H2O. Radio-HPLC was performed with an Agilent 1200 HPLC system 
equipped with a 1200 Series Diode Array Detector and a GABI Star NaI(Tl) scintillation 
detector. The system was used for purification as well as characterization of radiotracers. 
General procedure for preparation of compounds [
18
F]23 and [
18
F]27. [18F]Fluoride in 
water was trapped on a Sep-Pak® QMA cartridge and released with 0.5 ml of a solution of 
Kryptofix 222 (30 mM) and potassium carbonate (7.5 mM) dissolved in acetonitrile: water (85: 
15). After removing the solvent by heating at 90 °C under a stream of nitrogen, acetonitrile (0.5 
ml) was added, and the distillation was continued at 90 °C. This procedure was repeated, the vial 
was subsequently capped and the mixture was allowed to come to room temperature. The 
respective mesylate precursor (4 mg in 0.2 ml anhydrous DMSO) was added and the reaction 
was stirred at 90 °C for 20 min. After quenching with 0.8 ml water the crude mixture was 
purified by HPLC using a Chromolith® SemiPrep RP18-e column (100 × 10 mm) at room 
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 temperature. The mobile phase consisted of water and methanol (each containing 0.5% TFA). 
Gradient elution starting with 30% methanol content that was increased to 70% in 9 min allowed 
for isolation of the radioactive product. The obtained solution was diluted with 20 ml water, 
trapped on a Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with 
0.5 ml ethanol. After having reduced the volume to 100 µl under a stream of nitrogen, the 
solution was diluted with saline to give a final ethanol concentration of 5% and sterilized by 
filtration. 
[
18
F]4-(4-Benzhydrylpiperazin-1-yl)-2-fluorobutyl acetate ([
18
F]23). Starting with 1.2 GBq 
fluoride-18 and using precursor 52, the synthetic procedure afforded 182 MBq of formulated 
[18F]23 (13% overall RCY). Quality control was performed on a Chromolith® Performance 
RP18-e column (100 × 4.6 mm) using water and methanol (each containing 0.5% TFA; gradient 
elution at a flow rate of 3 ml/min starting with 30% methanol content that was increased to 90% 
in 9 min). The radiochemical purity was 100% and the identity of the radiochemical product was 
confirmed by co-elution with the non-radioactive analogue (RT = 4.6 min). 
 [
18
F]2-Fluoro-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl acetate ([
18
F]27). 
Starting with 1.0 GBq fluoride-18 and using precursor 56, the synthetic procedure afforded 105 
MBq of formulated [18F]27 (19% overall RCY). Quality control was performed on a 
Chromolith® Performance RP18-e column (100 × 4.6 mm) using water and methanol (each 
containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min starting with 30% methanol 
content that was increased to 90% in 9 min). The radiochemical purity was 100% and the 
identity of the radiochemical product was confirmed by co-elution with the non-radioactive 
analogue (RT = 4.5 min). 
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 [
18
F]4-(4-((4-Fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)butyl acetate 
([
18
F]38). [18F]Fluoride in water (1.2 GBq) was trapped on a Sep-Pak® QMA cartridge, released 
with 0.5 ml of a solution of Kryptofix 222 (30 mM) and potassium hydrogen carbonate (30 mM) 
dissolved in acetonitrile: water (85: 15). After removing the solvent by heating at 90 °C under a 
stream of nitrogen, acetonitrile (0.5 ml) was added, and the distillation was continued at 90 °C. 
This procedure was repeated and the reaction vial was subsequently capped. Compound 62 (4 
mg) dissolved in DMSO (0.5 ml) was subsequently added and the mixture was stirred at 110 °C 
for 15 min. The reaction was quenched and further diluted with water to a volume of 20 ml. This 
solution was filtered over a Sep-Pak® SPE C-18 light cartridge. The radiolabeled product was 
released with acetonitrile (1 ml), which was subsequently evaporated under a stream of nitrogen. 
The dry crude was taken up in THF (100 µl). Phenylmagnesium bromide (100 µl of a 1 M 
solution in THF) was added and the solution reacted at 90 °C for 30 min. After cooling, the 
reaction was quenched with formate buffer (pH 3; 1.8 ml) and purified by HPLC using a 
Chromolith® SemiPrep RP18-e column (100 × 10 mm) at room temperature. The mobile phase 
consisted of water and methanol (each containing 0.5% TFA). Gradient elution starting with 
10% methanol content that was increased to 55% in 12 min and further to 90% in 3 min allowed 
for isolation of [18F]4-(4-((4-fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)butan-1-ol 
([18F]39). The obtained solution was diluted with water to a final volume of 20 ml, trapped on a 
Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with acetonitrile 
(0.5 ml). TEA (50 µl) and acetyl chloride (25 µl) were added and the solution was stirred for 15 
min at ambient temperature. The reaction was quenched with water (1.4 ml) and the product was 
purified by HPLC using the same gradient that was used for purification of [18F]39. The obtained 
solution was diluted with water to a final volume of 20 ml, trapped on a Sep-Pak® SPE C-18 
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 light cartridge, and the radiolabeled product was released with 0.5 ml ethanol. After having 
reduced the volume to 100 µl under a stream of nitrogen, the solution was diluted with saline to 
give a final ethanol concentration of 5% and sterilized by filtration. Starting with 3.0 GBq 
fluoride-18, the three-step synthetic procedure afforded 13.4 MBq of formulated [18F]38 (6% 
overall RCY). Quality control was performed on a Chromolith® Performance RP18-e column 
(100 × 4.6 mm) using water and methanol (each containing 0.5% TFA; gradient elution at a flow 
rate of 3 ml/min starting with 10% methanol content that was increased to 55% in 12 min and 
further to 90% in 3 min). The radiochemical purity was 98% and the identity of the 
radiochemical product was confirmed by co-elution with the non-radioactive analogue (RT = 9.5 
min). 
[
18
F]4-(4-((4-fluorophenyl)(hydroxy)(phenyl)methyl)piperidin-1-yl)butan-1-ol ([
18
F]39). 
The compound was synthesized as described in the recipe for [18F]38. After HPLC 
purification, the obtained solution was diluted with water to a final volume of 20 ml, trapped on 
a Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with 0.5 ml 
ethanol. After having reduced the volume to 100 µl under a stream of nitrogen, the solution was 
diluted with saline to give a final ethanol concentration of 5% and sterilized by filtration. The 
synthetic procedure afforded 28.4 MBq of formulated [18F]39 (6% overall RCY). Quality control 
was performed on a Chromolith® Performance RP18-e column (100 × 4.6 mm) using water and 
methanol (each containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min starting with 
10% methanol content that was increased to 55% in 12 min and further to 90% in 3 min). The 
radiochemical purity was 100% and the identity of the radiochemical product was confirmed by 
co-elution with the non-radioactive analogue (RT = 7.8 min). 
Page 55 of 104
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 General procedure for preparation of alcohols [
18
F]40 and [
18
F]46. [18F]Fluoride in water 
was trapped on a Sep-Pak® QMA cartridge, released with 0.5 ml of a solution of Kryptofix 222 
(30 mM) and potassium hydrogen carbonate (30 mM) dissolved in acetonitrile: water (85: 15). 
After removing the solvent by heating at 90 °C under a stream of nitrogen, acetonitrile (0.5 ml) 
was added, and the distillation was continued at 90 °C. This procedure was repeated and the 
reaction vial was subsequently capped. The respective sulfonium triflate precursor dissolved in 
DMSO (0.5 ml) was added and the mixture was stirred at 110 °C for 15 min. The reaction was 
quenched and further diluted with water to a volume of 20 ml. This solution was filtered over a 
Sep-Pak® SPE C-18 light cartridge. The radiolabeled product was released with HCl in ethanol 
(1.25 M, 0.5 ml). The filtrate was heated at 90 °C for 15 min. After cooling, the reaction was 
quenched with water (1.5 ml) and purified by HPLC using a Chromolith® SemiPrep RP18-e 
column (100 × 10 mm) at room temperature. The mobile phase consisted of water and methanol 
(each containing 0.5% TFA). Gradient elution starting with 10% methanol content that was 
increased to 55% in 12 min and further to 90% in 3 min allowed for isolation of the radioactive 
product. The obtained solution was diluted with water to a final volume of 20 ml, trapped on a 
Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with 0.5 ml 
ethanol. After having reduced the volume to 100 µl under a stream of nitrogen, the solution was 
diluted with saline to give a final ethanol concentration of 5% and sterilized by filtration.  
 [
18
F]4-(4-((4-Fluorophenyl)(phenyl)methylene)piperidin-1-yl)butan-1-ol ([
18
F]40). 
Starting with 1.5–2.5 GBq fluoride-18, labeling of compound 70 followed by hydrolysis gave 
[18F]40 in 5–10% overall RCY. Quality control was performed on a Chromolith® Performance 
RP18-e column (100 × 4.6 mm) using water and methanol (each containing 0.5% TFA; gradient 
elution at a flow rate of 3 ml/min starting with 10% methanol content that was increased to 55% 
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 in 12 min and further to 90% in 3 min). The radiochemical purity was in the range of 98–100% 
and the identity of the radiochemical product was confirmed by co-elution with the non-
radioactive analogue (RT = 12.7 min).  
[
18
F](4-Fluorophenyl)(1-(4-hydroxybutyl)piperidin-4-yl)methanone ([
18
F]46). Starting 
with 1.75 GBq fluoride-18, labeling of compound 62 followed by hydrolysis gave 36.4 MBq of 
formulated [18F]46 (7% overall RCY). Quality control was performed by radio-HPLC using an 
analytical Chromolith® Performance RP18-e column (100 × 4.6 mm) using water and methanol 
(each containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min starting with 1% 
methanol content that was increased to 40% in 15). The radiochemical purity was 96% and the 
identity of the radiochemical product was confirmed by co-elution with the non-radioactive 
analogue (RT = 6.8 min). 
[
18
F]4-(4-((4-fluorophenyl)(phenyl)methylene)piperidin-1-yl)butanal ([
18
F]42). 
[18F]Fluoride in water (1.78 GBq) was trapped on a Sep-Pak® QMA cartridge, released with 0.5 
ml of a solution of Kryptofix 222 (30 mM) and potassium hydrogen carbonate (30 mM) 
dissolved in acetonitrile: water (85: 15). After removing the solvent by heating at 90 °C under a 
stream of nitrogen, acetonitrile (0.5 ml) was added, and the distillation was continued at 90 °C. 
This procedure was repeated and the reaction vial was subsequently capped. Compound 74 
dissolved in DMSO (0.5 ml) was added and the mixture was stirred at 110 °C for 15 min. The 
reaction was quenched and further diluted with water to a volume of 20 ml. This solution was 
filtered over a Sep-Pak® SPE C-18 light cartridge. The radiolabeled product was released with 
THF (0.5 ml), and HCl (1 M; 1.5 ml) was added. This solution was heated at 90 °C for 15 min. 
After cooling, the crude mixture was purified by HPLC using a Chromolith® SemiPrep RP18-e 
column (100 × 10 mm) at room temperature. The mobile phase consisted of water and methanol 
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 (each containing 0.5% TFA). Gradient elution starting with 10% methanol content that was 
increased to 70% in 20 min and further to 90% in 5 min allowed for isolation of the radioactive 
product. The obtained solution was diluted with water to a final volume of 20 ml, trapped on a 
Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with 0.5 ml 
ethanol. After having reduced the volume to 100 µl under a stream of nitrogen, the solution was 
diluted with saline to give a final ethanol concentration of 5% and sterilized by filtration 
resulting in 37.2 MBq of formulated [18F]42 (6% overall RCY). Quality control was performed 
by radio-HPLC using an analytical Agilent Zorbax® Eclipse XDB column (150 × 4.6 mm) using 
water and methanol (each containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min 
starting with 30% methanol content that was increased to 90% in 15). The radiochemical purity 
was 96% and the identity of the radiochemical product was confirmed by co-elution with the 
non-radioactive analogue (RT = 16.4 min). 
General procedure for preparation of esters [
18
F]43 and [
18
F]47. [18F]Fluoride in water was 
trapped on a Sep-Pak® QMA cartridge, released with 0.5 ml of a solution of Kryptofix 222 (30 
mM) and potassium hydrogen carbonate (30 mM) dissolved in acetonitrile: water (85: 15). After 
removing the solvent by heating at 90 °C under a stream of nitrogen, acetonitrile (0.5 ml) was 
added, and the distillation was continued at 90 °C. This procedure was repeated and the reaction 
vial was subsequently capped. The respective sulfonium triflate dissolved in DMSO (0.5 ml) was 
subsequently added and the mixture was stirred at 110 °C for 15 min. The reaction was quenched 
with water (1.5 ml) and the mixture was purified by HPLC using a Chromolith® SemiPrep RP18-
e column (100 × 10 mm) at room temperature. The mobile phase consisted of water and 
methanol (each containing 0.5% TFA). Gradient elution starting with 10% methanol content that 
was increased to 55% in 12 min and further to 90% in 3 min allowed for isolation of the 
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 radioactive product. The obtained solution was diluted with water to a final volume of 20 ml, 
trapped on a Sep-Pak® SPE C-18 light cartridge, and the radiolabeled product was released with 
0.5 ml ethanol. After having reduced the volume to 100 µl under a stream of nitrogen, the 
solution was diluted with saline to give a final ethanol concentration of 5% and sterilized by 
filtration.  
[
18
F]Ethyl 4-(4-((4-fluorophenyl)(phenyl)methylene)piperidin-1-yl)butanoate ([
18
F]43). 
Starting with 1.7 GBq fluoride-18, labeling of compound 72 gave 26–30 MBq (n = 2) of 
formulated [18F]43 (3% overall RCY). Quality control was performed on a Chromolith® 
Performance RP18-e column (100 × 4.6 mm) using water and methanol (each containing 0.5% 
TFA; gradient elution at a flow rate of 3 ml/min starting with 10% methanol content that was 
increased to 55% in 12 min and further to 90% in 3 min). The radiochemical purity was 99% and 
the identity of the radiochemical product was confirmed by co-elution with the non-radioactive 
analogue (RT = 11.6 min).  
[
18
F]Ethyl 4-(4-(4-fluorobenzoyl)piperidin-1-yl)butanoate ([
18
F]47). Starting with 1.4 GBq 
fluoride-18, labeling of compound 64 gave 136 MBq of formulated [18F]47 (18% overall RCY). 
Quality control was performed on a Chromolith® Performance RP18-e column (100 × 4.6 mm) 
using water and methanol (each containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min 
starting with 10% methanol content that was increased to 55% in 12 min and further to 90% in 3 
min). The radiochemical purity was 100% and the identity of the radiochemical product was 
confirmed by co-elution with the non-radioactive analogue (RT = 10.2 min). 
[
18
F]4-(4-((4-fluorophenyl)(phenyl)methylene)piperidin-1-yl)butanoic acid ([
18
F]44). 
[18F]44 was prepared from [18F]43 using the synthetic procedure described above. After the 
labeling reaction, the crude mixture was diluted with water to a volume of 20 ml and filtered 
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 over a Sep-Pak® SPE C-18 light cartridge. The radiolabeled product was released from the 
cartridge with ethanol (1.0 ml), to which was added aqueous NaOH (1 M; 0.5 ml). The ester was 
hydrolysed in an open vial for 15 min at 90 °C and the resulting carboxylic acid was 
subsequently purified by HPLC using a Chromolith® SemiPrep RP18-e column (100 × 10 mm) 
at room temperature. The mobile phase consisted of water and methanol (each containing 0.5% 
TFA). Gradient elution starting with 10% methanol content that was increased to 55% in 12 min 
and further to 90% in 3 min allowed for isolation of the radioactive product. The isolated product 
was re-formulated as described above. Starting with 1.0–1.6 GBq fluoride-18, the two-step 
synthetic procedure afforded 10–15 MBq of formulated [18F]44 (2.3–2.6% overall RCY). Quality 
control was performed on a Chromolith® Performance RP18-e column (100 × 4.6 mm) using 
water and methanol (each containing 0.5% TFA; gradient elution at a flow rate of 3 ml/min 
starting with 10% methanol content that was increased to 55% in 12 min and further to 90% in 3 
min). The radiochemical purity was 100% and the identity of the radiochemical product was 
confirmed by co-elution with the non-radioactive analogue (RT = 8.7 min). 
P-gp ATPase activity assay. The Pgp-Glo™ assay (Promega) was performed following the 
manufacturer’s instructions.34 Briefly, a membrane preparation from Sf9 cells expressing the 
recombinant human P-gp was incubated with the respective test compound (20 µM) and ATP (5 
mM) for 40 minutes at 37 °C. Sodium orthovanadate (20 µM) and verapamil (200 µM) were 
added as negative and positive control, respectively. After this time, the enzyme luciferase and 
the corresponding substrate luciferin were added, and incubation was continued for 20 minutes. 
Quantification was carried out by determination of luminescence. Results are given as reduction 
of luminescence (the more avid a substrate the more pronounced is the reduction of 
luminescence). 
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 hH1R binding assay. CHO-K1 cells stably expressing the hH1R were washed with 10 ml ice-
cold PBS buffer (140 mM NaCl, 3 mM KCl, 1.5 mM KH2PO4, 8 mM NaHPO4, pH 7.4), scraped 
into ice-cold HEPES binding buffer (20 mM HEPES, 10 mM MgCl2, 100 mM NaCl, pH 7.4), 
and homogenized with sonication. Membranes were pelleted at 23,000 x g for 30 minutes at 4 
°C, homogenized in HEPES buffer using a hand potter, and stored in liquid nitrogen. Prior to 
experiments, cell membranes were thawed, homogenized with sonication at 4 °C into ice-cold 
HEPES binding buffer. Competition binding experiments were carried out incubating 
membranes, 35 µg/well in a final volume of 0.2 ml containing binding buffer and [3H]pyrilamine 
(1.0 nM; 27 Ci/mmol). Assays were run in triplicates with at least four appropriate 
concentrations between 1 nM and 1 µM of the test compound. Incubations were performed for 
120 min at 25 °C and shaking at 250 rpm. Non-specific binding was determined in the presence 
of 10 µM chlorpheniramine hydrogenmaleate. Bound radioligand was separated from free 
radioligand by filtration through GF/B filters pre-treated with 0.3% (mass/vol) 
polyethyleneimine using an Inotech cell harvester. Unbound radioligand was removed with four 
washes of 5 ml of ice-cold HEPES buffer.35 
Animals. All animal work at UCL was performed in compliance with the United Kingdom 
Home Office’s Animals (Scientific Procedures) Act 1986 and with approval of the University 
College London (UCL) Animal Ethics Committee. Female wild-type albino mice (FVB or 
Balb/C, Charles River Laboratories, Margate, UK) were allowed to acclimatize for at least one 
week at the animal facilities at the UCL Centre for Advanced Biomedical Imaging, and they 
were given food and water ad libitum. When used for experiments, they were eight to eleven 
weeks old and weighing approximately 20 g. For PET scanning experiments at AIT, wild-type 
FVB as well as P-gp knock-out mice were obtained from Taconic (Germantown, USA). The 
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 study was approved by the local animal welfare committee (Amt der Niederösterreichischen 
Landesregierung) and all experimental procedures were performed in accordance with the 
European Communities Council Directive of September 22, 2010 (2010/63/EU). 
Biodistribution Studies. Biodistribution studies were performed at UCL’s Centre for 
Advanced Biomedical Imaging. The respective radiotracer (0.5–3 MBq formulated in saline 
solution containing max. 5% ethanol) was administered intravenously into the tail vein of female 
wild type albino mice (Balb/C or FVB) without anesthesia. At designated time points between 
five minutes and two hours after tracer injection, animals were anesthetized with isoflurane (5% 
mixed with medical air at a flow of 2 ml/min) and the blood was taken by cardiac puncture. Mice 
were subsequently sacrificed by cervical dislocation. The organs of interest were sampled, 
weighed, and the radioactivity content was measured by automated gamma counting (Perkin 
Elmer Wizard2). Results were expressed as % ID/g bodyweight. All experiments were performed 
in duplicate or triplicate. For blocking studies with tariquidar, 15 mg/kg of the P-gp inhibitor 
formulated in 300 µl of a 2.5% glucose solution was administered intravenously into the tail vein 
two hours before tracer injection. The dose was administered slowly over the course of 
approximately 2 min. 
Metabolite Analysis. Metabolite analysis was performed as part of the biodistribution studies. 
Blood samples were collected in heparin-coated tubes and an aliquot (20 µl) was taken for 
gamma counting. After centrifugation (3 min, 13,000 rpm), the plasma was separated. Plasma 
proteins were subsequently precipitated with cold ethanol (500 µl) and samples were centrifuged 
(3 min, 13,000 rpm). 500 µl of the resulting supernatant were separated from the pellet, diluted 
with water (500 µl) and analyzed by radio-HPLC, using a Phenomenex Luna® C-8 (5 µm, 150 x 
4.6 mm) or an Agilent Zorbax® Eclipse XDB C-18 (5 µm, 100 × 4.6 mm) analytical column at 
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 room temperature. The mobile phase consisted of water and methanol containing 0.02% NH4OH 
and was used for gradient elution (from 30% of methanol to 95% in 15 min, followed by 
isocratic elution with 95% for 5 min). The flow rate was 1 ml/min and the UV absorbance 
detector was set at 254 nm. Brains were homogenized in a mixture of water (500 µl) and ethanol 
(500 µl). Samples were centrifuged (3 min, 13,000 rpm), the resulting supernatant was separated 
and deproteinated by adding ethanol a second time (500 µl). After vortexing and centrifugation 
(3 min, 13,000 rpm), the clear supernatant (500 µl) was separated from the pellet, diluted with 
water (500 µl) and analyzed by radio-HPLC, using the method reported above. The recovery of 
radioactivity in the investigated samples from both plasma and brain was almost quantitative (> 
95%). All experiments were performed in triplicate. 
PET scans. Dynamic PET imaging was performed using a µPET Focus220 scanner (Siemens 
Medical Solutions, Knoxville, TN) at AIT and a nanoScan® PET-CT system manufactured by 
Mediso (Medical Imaging Systems, Budapest, Hungary) at UCL, respectively. Mice were 
anaesthetized with isoflurane (2% in oxygen) and placed on the preheated bed of the scanner (set 
at 38 °C). The respective radiotracer (5–10 MBq in 100–250 µl saline solution) was injected into 
the tail vein via intravenous cannulation. After injection, the catheter was carefully removed. 
Breathing rate and body temperature of the animals were closely monitored during the dynamic 
PET scans and, if necessary, the isoflurane dose was adjusted. Scans were recorded over two 
hours, and the animals were subsequently sacrificed by cervical dislocation. Quantification of 
tissue uptake was carried out using the image analysis software Amide at AIT and the software 
package VivoQuant 1.23 (inviCRO, Boston, USA) at UCL, respectively. 
Blocking studies. Tariquidar (15 mg/kg bodyweight; formulated in 2.5% glucose solution) or 
elacridar (10 mg/kg bodyweight; formulated in 20% ethanol in water) were injected slowly (over 
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 the course of 1–2 min) into the tail vein 90 min before tracer administration in order to achieve 
full inhibition of the respective efflux transporters. Control animals received vehicle or saline. 
This was carried out without anesthesia, and mice were allowed food and water ad libitum in 
between the injections.  
Analysis of tracer kinetics. In the absence of an arterial input function, we used a simple 
model to describe the uptake of the pro-drug tracer from the blood, metabolism and trapping of 
the tracer in the brain, and the washout of the metabolically activated tracer. Whole-brain time-
activity curves were analyzed by fitting the sum of a mono-exponential function and a constant 
to the time-activity curve data from 10 min p.i. The amplitude of the exponential term A1 would 
correspond to tracer being washed out from the brain with s representing the efflux rate, and the 
constant term A2 to tracer that gets trapped in brain tissue. 
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ABBREVIATIONS 
ABC, adenosine triphosphate-binding cassette; BBB, blood-brain barrier; BCRP, breast cancer 
resistance protein; CNS, central nervous system; hH1R, human histamine H1 receptor; HPLC, 
high performance liquid chromatography; ID/g, injected dose per gram tissue; MDR, multiple 
drug resistance; MEM, metabolite extrusion method; PET, positron emission tomography; P-gp, 
P-glycoprotein; p.i., post injection; RCY, radiochemical yield. 
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 TABLE 
Table 1. Blood and Brain Uptake of Tracer Candidates a) 
Compound Scaffold Pro-drug moiety Tissue uptake (% ID/g) Brain/blood 
   Blood Brain  
   5 30 5 30 5 30 
   min p.i. min p.i. min p.i. 
[
18
F]23 
 
 
1.8 1.4 5.8 1.6 3.2 1.1 
[
18
F]27 
 
 2.3 3.5 7.2 4.2 3.1 1.2 
[
18
F]38 
 
 
0.8 0.8 1.8 1.8 2.3 2.3 
[
18
F]39   0.8 0.7 1.0 1.0 1.3 1.4 
[
18
F]40 
 
 0.9 1.0 9.4 7.3 10.4 7.3 
[
18
F]42   1.4 1.6 3.1 3.4 2.2 2.1 
[
18
F]43  
 
2.5 3.7 2.9 4.9 1.2 1.3 
[
18
F]44  
 
3.0 1.5 1.3 1.7 0.4 1.1 
[
18
F]46 
 
 1.3 1.5 6.5 2.7 5.0 1.8 
[
18
F]47  
 
4.0 0.7 3.1 0.9 0.8 1.3 
a) Biodistribution studies in wild-type mice were performed in duplicate or triplicate: organs of 
interest were collected at 5 and 30 min p.i., respectively, and analyzed by gamma-counting; 
average radioactivity uptake given as % injected dose per gram bodyweight (% ID/g). 
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 FIGURE LEGENDS 
Figure 1. Illustration of the study design. A) Structures of hydroxyzine and terfenadine, which 
were used as templates for the development of the pro-drug tracers, and their oxidative 
metabolism to cetirizine and fexofenadine, respectively; B) Depiction of the structural 
modifications that were investigated in this study. 
Figure 2. Fluorinated non-radioactive analogues of potential pro-drug tracers. 
Figure 3. Stimulation of P-gp ATPase activity by selected compounds. Reduction of 
luminescence in counts per minute; all compounds except verapamil (200 µM) were tested at a 
concentration of 20 µM; experiments were performed in triplicate; abbreviations: Cet, cetirizine; 
Con, negative control sodium orthovanadate; Fex, fexofenadine; Ver, positive control verapamil. 
Figure 4. Organ distribution and metabolic profile of [18F]40 and [18F]44 in wild type FVB mice 
(n = 3). A) Blood and brain uptake of [18F]40 at 5, 15, 30, 45, 60, 90 and 120 min p.i. in % ID/g; 
B) Blood and brain uptake of [18F]44 at 5, 60 and 120 min p.i. in % ID/g; C/D) Metabolic profile 
of [18F]40 in brain and blood at 30, 60, 90 and 120 min p.i. as determined by radio-HPLC. 
Figure 5. Blocking studies. A) Brain (filled columns) and blood (dotted columns) uptake of 
[
18
F]40 before (black) and after administration of tariquidar (light grey) and elacridar (dark grey) 
in wild type FVB mice (n = 3; * p < 0.05); B) Whole brain time-activity curves from dynamic 
PET scans in untreated wild type mice (black circles), tariquidar-treated mice (light grey squares) 
and P-gp knockout mice (open triangles) (experiment performed at AIT); C) Whole brain time-
activity curves from dynamic PET scans in untreated wild type mice (black circles) and 
elacridar-treated mice (dark grey squares) (experiment performed at UCL).   
Page 75 of 104
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 SCHEME LEGENDS 
Scheme 1. Synthesis of simplified fexofenadine derivatives 
Caption: Reagents and conditions: (i) K2CO3, KI, CH3CN, 80 °C, 12 h; or: K2CO3, acetone, 60 
°C – rt, 12 h; (ii) oxalyl chloride, DMSO, TEA, DCM, < -50 °C, 30 min; (iii) KOH, H2O: THF: 
CH3OH = 2: 1: 1, MW, 70 °C, 15 min. 
Scheme 2. Synthesis of compounds 18-28 with an aliphatic fluorinated side chain 
Caption: Reagents and conditions: (i) DAST, DCM, 0 °C – rt, 3 h; (ii) NaOCH3, CH3OH, rt, 1 
h; (iii) TsCl, pyridine, DCM, 0 °C – rt, 12 h; (iv) 1-benzhydryl-piperazine (A)/diphenyl-
piperidin-4-yl-methanol (B), TEA, CH3CN, 70 °C, 6 h; (v) LiAlH4, THF, 0 °C – rt, 1 h; (vi) 
KOH, H2O: THF: CH3OH = 2: 1: 1, rt, 1 h; (vii) Ac2O, TEA, DCM, rt, 3 h. 
Scheme 3. Synthesis of the fluorinated scaffolds C-F 
Caption: Reagents and conditions: (i) PCC, celite, DCM, rt, 3 h; (ii) 4F-PhMgBr, THF, 0 – 60 
°C, 2 h; (iii) Dess-Martin periodinane, DCM, rt, 2 h; (iv) PhMgBr, THF, 0 – 60 °C, 1 h; (v) HCl, 
dioxane, THF, rt, 12 h; (vi) TFA, DCM, rt, 3 h. 
Scheme 4. Synthesis of precursors for radiolabeling of aliphatic residues 
Caption: Reagents and conditions: (i) TsCl, pyridine, DCM, 0 °C – rt, 12 h; (ii) 1-benzhydryl-
piperazine (a)/diphenyl-piperidin-4-yl-methanol (b), TEA, CH3CN, 70 °C, 6 h; (iii) PTSA, 
CH3OH, 40 °C, 4 h; (iv) Ac2O, TEA, DCM, 0 °C – rt, 3 h; (v) MsCl, TEA, DCM, rt, 1 h. 
Scheme 5. Synthesis of triarylsulfonium triflates as precursors for labeling with fluoride-18 
Caption: Reagents and conditions: (i) 1. n-BuLi, THF, -78 °C, 30 min; 2. 58, THF, -78 °C – 0 
°C, 30 min; (ii) HCl, THF, rt, 12 h; (iii) bromoalkane, K2CO3, acetone, 60 °C – rt, 12 h; (iv) (Ph) 
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 2I
+ . CF3O3S
−, Cu(II) benzoate, CHF3O3S, C6H5Cl, 125 °C, 1 h; (v) PhMgBr, THF, 0 °C – rt, 3 h; 
(vi) TFA, DCM, 0 °C – rt, 2 h; (vii) (4-OCH3-Ph)2I
+ . CF3O3S
− (75), Cu(II) benzoate, CHF3O3S, 
C6H5Cl, 125 °C, 1 h. 
Scheme 6. Radiosynthesis of tracers [18F]23 and [18F]27 
Caption: Reagents and conditions: (i) [18F]F−, K2CO3, K222, DMSO, 90 °C, 20 min. 
Scheme 7. Radiosynthesis of ketanserin- and fexofenadine-like pro-drug tracer candidates 
Caption: Reagents and conditions: (i) [18F]F−, KHCO3, K222, DMSO, 110 °C, 15 min; (ii) HCl, 
C2H5OH, 90 °C, 15 min; (iii) PhMgBr, THF, 90 °C, 30 min; (iv) AcCl, CH3CN, rt, 15 min. 
Scheme 8. Radiosynthesis of ritanserin-like pro-drug tracer candidates 
Caption: Reagents and conditions: (i) [18F]F−, KHCO3, K222, DMSO, 110 °C, 15 min; (ii) HCl, 
C2H5OH, 90 °C, 15 min; (iii) NaOH, C2H5OH, 90 °C, 15 min; (iv) HCl, THF, 90 °C, 15 min. 
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